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Examining CD8+ and CD4+ T cell responses after primary Yellow Fever vaccination in
a cohort of 210 volunteers, we have identified and tetramer-validated 92 CD8+ and
50 CD4+ T cell epitopes, many inducing strong and prevalent (i.e., immunodominant)
T cell responses. Restricted by 40 and 14 HLA-class I and II allotypes, respectively,
these responses have wide population coverage andmight be of considerable academic,
diagnostic and therapeutic interest. The broad coverage of epitopes and HLA overcame
the otherwise confounding effects of HLA diversity and non-HLA background providing
the first evidence of T cell immunodomination in humans. Also, double-staining of
CD4+ T cells with tetramers representing the same HLA-binding core, albeit with
different flanking regions, demonstrated an extensive diversification of the specificities
of many CD4+ T cell responses. We suggest that this could reduce the risk of
pathogen escape, and that multi-tetramer staining is required to reveal the true
magnitude and diversity of CD4+ T cell responses. Our T cell epitope discovery
approach uses a combination of (1) overlapping peptides representing the entire
Yellow Fever virus proteome to search for peptides containing CD4+ and/or CD8+
T cell epitopes, (2) predictors of peptide-HLA binding to suggest epitopes and their
restricting HLA allotypes, (3) generation of peptide-HLA tetramers to identify T cell
epitopes, and (4) analysis of ex vivo T cell responses to validate the same. This
approach is systematic, exhaustive, and can be done in any individual of any HLA
haplotype. It is all-inclusive in the sense that it includes all protein antigens and peptide
epitopes, and encompasses both CD4+ and CD8+ T cell epitopes. It is efficient
and, importantly, reduces the false discovery rate. The unbiased nature of the T cell
epitope discovery approach presented here should support the refinement of future
peptide-HLA class I and II predictors and tetramer technologies, which eventually should
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cover all HLA class I and II isotypes. We believe that future investigations of emerging
pathogens (e.g., SARS-CoV-2) should include population-wide T cell epitope discovery
using blood samples from patients, convalescents and/or long-term survivors, whomight
all hold important information on T cell epitopes and responses.
Keywords: yellow fever vaccination, immunogenicity, CD4+ and CD8+ T cell epitope discovery, forward-reverse
immunology, immunodominance and immunodomination, peptide-MHC tetramers, peptide-MHC predictors
INTRODUCTION
The immune system attempts to protect its host against invading
pathogens; yet, it can also cause serious pathology. The ability to
discriminate between foreign and self is key to exerting immune
protection without inflicting immune pathology. Immune
recognition is therefore of immense interest and efficient
methods to identify and validate immune epitopes are a high
priority. In this context, T cells, which effectively orchestrate the
overall immune response, are of particular interest. T cells are
specific for compound ligands consisting of peptides, generated
intracellularly by proteolytic degradation of protein antigens,
which are presented in the context of major histocompatibility
complex (MHC) [or human leucocyte antigens (HLA)]molecules
on the surface of antigen presenting cells (APC) (1). The
interaction between peptide and HLA is specific; the resulting
HLA-mediated T cell epitope selection process being greatly
diversified by the polygenic and polymorphic nature of the
HLA. This significantly affects the peptide-binding specificity of
the set of HLA molecules that are available to any given host;
something that effectively individualizes our immune responses.
Although other events are also involved in antigen processing
and presentation, the single most selective event is that of
peptide-HLA binding. It is estimated that ca. 0.5% of all possible
peptide-HLA combinations are of a sufficiently high affinity that
they potentially, but not necessarily, could be immunogenic (2).
Major efforts have been devoted to understand, quantitate and
preferably predict peptide-HLA binding as a means to identify
T cell epitopes. Proposed in 1999, the “human MHC project”
aims at mapping all human MHC (or HLA) specificities (3, 4).
Established in 2004, the “Immune Epitope Database” (IEDB)
has become an authoritative repository of HLA binding peptides
and T cell epitopes, and of methods to predict these (5). The
recent breakthrough in cancer immunotherapy has reinforced
the interest in fast and efficient methods to identify T cell
epitopes with special emphasis on identifying immunogenic
neoepitopes for personalized cancer immunotherapy. Thus,
several recent international research efforts, such as the
“Human ImmunoPeptidome Project and Consortium,” “Tumor
Neoantigen Selection Alliance” and others, have focused on
T cell epitope discovery. Employing recent advances in mass
spectrometry to perform large-scale identification of peptides
eluted of HLA molecules, these efforts promise to identify
natural ligands thereby capturing information on both antigen
processing and HLA binding (6).
Over the past decades, substantial progress has been made
on predicting peptide-HLA interactions, particularly for HLA
class I (HLA-I), which restricts CD8+ cytotoxic T cells (CTL’s),
and to a lesser degree on predictions for HLA class II (HLA-II),
which restricts CD4+ helper T cells (Th) (7–15). State-of-the-
art predictors such as NetMHCpan, an artificial neural network
method based on a large collection of experimental peptide-HLA-
I binding data, can successfully identify 96.5% of CD8+ T cell
epitopes, while rejecting 98.5% of non-epitopes (16). However,
considering that only 1 of 2,000 (2) to 8,000 (17) random peptides
is a T cell immunogen in the context of a given HLA molecule,
even a rejection rate as high as 98.5% translates into a high
false discovery rate (FDR) (8, 10, 11, 18). This is a general
problem of current peptide-HLA binding predictors (10, 11),
and it is particularly problematic when trying to develop a
neoepitope-specific, personalized cancer immunotherapy where
timely delivery of a few unique cancer neoepitopes is of
paramount importance; something that potentially could be
achieved with even better predictors (8, 19–21).
Yellow Fever Virus (YFV) is a mosquito-borne flavivirus (i.e.,
a ssRNA virus) (22, 23). It remains an important human pathogen
despite the existence of an effective live attenuated vaccine (24).
Particularly relevant to this study, previous analyses of the CD8+
T cell response against a limited number of epitopes have revealed
that vaccination with this live vaccine represents an excellent
model for studying the host response to a viral infection (25, 26).
The main advantages are that the precise time and the exact
identity of the immune challenge are both known [note that
the vaccine strain used here is known to be stable (27)]; issues
that otherwise might complicate the interpretation of immune
responses observed in patients that are naturally infected with a
variable pathogen.
Here, we have generated a comprehensive, population-wide
T cell epitope discovery approach with a much-reduced FDR,
and used it to identify and validate immunodominant CD8+
and CD4+ T cell epitopes in a cohort of 210 HLA-typed,
primary YFV vaccinees. This involves using a “forward (or direct)
immunology” approach, where you start with a specific T cell
response of interest and then search for the epitope(s) being
recognized (28, 29), to perform an initial identification of T
cell stimulatory peptides. Subsequently, a “reverse immunology”
approach, where you start by predicting possible T cell epitopes
and then search for a T cell response of the corresponding
specificity (30, 31) was used, to perform a final identification and
validation of the underlying specific T cell epitopes and their
HLA restriction elements. Fromhere on, this approach is denoted
as a “hybrid forward-reverse immunology” (HFRI) approach.
Briefly, in the “forward immunology” step, PBMC’s obtained 2–
3 weeks after primary YFV vaccination were ex vivo stimulated
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with an overlapping peptide library representing the entire
3,411 amino acid YFV proteome and tested by an IFNγ-specific
intracellular cytokine secretion (ICS) assay thereby identifying
CD8+ and CD4+ T cell stimulatory YFV-derived peptides. In the
subsequent “reverse immunology” step, predictors were used to
select appropriate peptide-HLA combinations for the generation
of peptide-HLA tetramers, which then were used to identify and
validate the underlying T cell epitopes and their HLA restriction
elements. Applying this HFRI approach to T cell epitope
discovery in 50 YFV vaccinees, we identified and tetramer-
validated 92 CD8+ and 50 CD4+ T cell epitopes covering
40 HLA-I and 14 HLA-II allotypes, respectively (note that he
tetramer-validation step could not be performed exhaustively for
the CD4+ T cell epitope discovery process and that the true
number of CD4+ T cell epitopes probably was many times larger
than the 50 validated CD4+ T cell epitopes reported here).With a
cohort of 210 YFV vaccinees, the prevalence of responses against
the CD8+ T cell epitopes could be examined. About a third (31%)
of these epitopes were recognized in >90% of the individuals
expressing the HLA-I in question. By this token, they could be
considered strongly immunodominant. We conclude that T cell
epitope discovery using this HFRI approach is highly efficient,
in particular when examining larger populations responding
to the same pathogen (e.g., an infectious pathogen e.g., SARS,
Ebola, Zika, SARS-CoV-2). Furthermore, we suggest that the
HFRI approach is unbiased and that the resulting T cell epitopes
should serve as a valuable benchmark for future improvements of
predictive algorithms of immunogenicity.
RESULTS
Obtaining Blood Samples From HLA-Typed
Yellow Fever Vaccinees
Primary vaccination with the attenuated YFV vaccine, 17D-204,
is known to trigger a prompt and vigorous cellular immune
reaction (25, 26). Here, 210 vaccinees were recruited, and
peripheral blood mononuclear cells (PBMC) were prepared from
50- to 200-ml blood samples obtained before and ca. 2 weeks after
primary vaccination, respectively (26). The typical yield from
the latter was ca. 450 million PBMC. All vaccinees were HLA
typed at high-resolution (i.e., 4 digit) including all nine classical,
polymorphic HLA loci (i.e., HLA-A, B, C, DRB1, DRB3/4/5,
DQA1, DQB1, DPA1, and DPB1) (26).
Overlapping Peptides Representing the
Entire Yellow Fever Virus Proteome
The 17D-204 vaccine encodes a single polyprotein precursor of
3,411 amino acids (aa), which is processed into 15 proteins. The
full genome (GenBank accession# X15062) and proteome (Swiss-
Prot accession# P03314) sequences of the 17D-204 have been
determined (32). A library of 850 overlapping 15 mer peptides
overlapping by 11 aa, spanning the entire YFV precursor protein
(essentially the YFV proteome), was generated. Additionally,
50 peptides representing potentially aberrant YFV translation
products were selected. Of the resulting 900 peptides, synthesis
failed for 30 peptides (3%) leaving 870 peptides for analysis.
Matrix-Based Screening Strategies
Since testing each of these peptides individually would exhaust
the available PBMC’s, the peptides were tested in pools. Initially,
the peptides were organized into a single 30×30 matrix from
which 30 “column pools” and 30 “row pools” were generated
leading to a total of 60 pools each containing ca. 30 different
peptides. Each peptide would be present in two pools: one
column and one row pool (Supplementary Figure S1A). The
intersections of stimulatory column and row pools should ideally
identify which peptide might be immunogenic and therefore
should be further investigated on an individual basis.
This 30×30 matrix strategy was initially tested using an ex-
vivo IFNγ ELISpot assay as readout. After the first 94 primary
vaccinated donors had been recruited, the average number of
positive column/row intersections was found to be 418 (range
26–870) (Figure 1A) suggesting that the hit rate from pools
containing 30 peptides was too high, at least in the setting of
this acute viral response, to be effective in eliminating non-
stimulatory peptides from further consideration.
To reduce the hit rate per peptide pool, the peptides
were re-organized into four smaller matrices, three 15×15
matrices and one 14×15. For each matrix, 14 to 15 column
pools and 15 row pools were generated leading to a total of
119 pools, which each contained 14 to 15 different peptides
(Supplementary Figure S1B). To further reduce the number of
relevant intersections, the IFNγ ELISpot assay was replaced by
an IFNγ intracellular cytokine staining (ICS) assay, which can
discriminate between CD8+ and CD4+ T cells and therefore
eliminate intersections with mismatched CD8+ and CD4+ T
cell responses. Furthermore, to increase the number of T
cells available for the ICS assay, PBMC were expanded in
four separate in vitro cultures containing a pool of ca. 225
peptides corresponding to each of the four matrices, respectively
(the potential bias introduced by this in vitro culture is
discussed in Supplementary Results and Discussion). After 8
days, each matrix-expanded PBMC culture was tested against
the appropriate row and column pools using IFNγ ICS as
readout. For comparison, 36 donors, which had already been
analyzed using the 30×30-matrix, ELISpot-based screening
strategy, were re-screened using the 4×(15×15)-matrix, ICS-
based screening strategy (Figures 1B–D). The aggregated CD4+
and CD8+ T cell responses were calculated for ICS responses
(denoted “All T cells” in Figure 1) and compared to those from
Elispot responses. The total number of intersections needing
deconvolution was significantly lower for the 4×(15×15 ICS
strategy [average intersections 253 (range 20–589)] than for
the 30×30 ELISpot strategy [average 418 (range 26–870), (p
< 0.0001, N = 36, Mann–Whitney U-test), Figures 1A,B].
The 253 intersections, which on average were detected by
the ICS-based screening strategy, could further be broken
down into an average of 80 (range 2–374) (Figure 1C)
and 197 (range 7–514) (Figure 1D) intersections representing
CD8+ and CD4+ T cell responses, respectively (30 of these
intersections were shared). The peptides corresponding to these
intersections were subsequently tested individually to identify
which of the intersections truly represented CD8+ and/or CD4+
T responses.
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FIGURE 1 | Comparing the number of peptide-containing peptides identified by the two different approaches. T cells obtained ex vivo from primary YFV vaccinees
were stimulated with matrix-derived pools of YFV peptides and responses were read by IFNγ-specific ELIspot or ICS. The peptides were distributed into matrixes,
column and row pools of peptides were generated, and used to test T cell stimulation. Intersections of stimulatory column and row pools putatively identified single
stimulatory peptides for further analysis (Supplementary Figure S3). (A) Peptides were distributed into one 30×30 matrix generating 30 + 30 = 60 pools, which
were used to stimulate T cell responses in 94 donors using an IFNγ-specific ELISpot assay as readout of all (i.e., CD4+ and CD8+) T cell responses [average 418
positive intersections (range 26–870)]. (B,C) Peptides were distributed into four ca. 15×15 matrices generating 4x(ca. 15 + 15) ca. 120 pools, which were used to
stimulate T cell responses in 36 donors using an IFNγ-specific ICS assay as readout of (B) all T cell responses [average 253 intersections (range 20–589)], (C) CD8+ T
cell responses [average 80 intersections (range 2–374), and (D] CD4+ T cell responses average 197 intersections (range 7–514). The symbols representing the 36
donors that were examined by both ELISpot and ICS have been shaded. Mann Whitney U test was used to determine the significance of the difference between the
indicated groups (***p < 0.0001).
Identification of Stimulatory 15mer
Peptides (Exemplified by Donor YF1067)
The complete screening and validation procedure is illustrated
using donor YF1067. The blood sample for donor YF1067
was collected at day 16 post vaccination, which is within the
time span of optimal post vaccination YFV responses (25, 26).
It gave a relatively high yield of 700 × 106 PBMC’s for the
subsequent epitope discovery effort. Donor YF1067 was initially
analyzed by the 30×30-matrix, IFNγ ELISpot-based screening
strategy where 690 positive intersections were identified. A
total (i.e., cumulative) YFV-specific response of 8000 SFU were
obtained suggesting a T cell response of considerable breath
and magnitude. Re-analyzing this donor using the four-matrix,
ICS-based screening strategy, the number of intersections for
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FIGURE 2 | T cell epitope screening strategy. (A) Identification of stimulatory 15mer peptides: PBMC’s from YFV vaccinated donors were divided into four cultures
and in vitro stimulated with peptide sublibraries corresponding to each of the four 15×15 peptide matrices. After 8 days, each sublibrary expanded PBMC culture was
tested by ICS against the matrix-specific row and column peptide pools. Subsequently, individual peptides representing stimulatory matrix intersections were analyzed
to identify single T cell stimulatory 15-mer peptides. (B) Identification of T cell epitopes and their HLA restriction elements: CD4+ T cell epitope deconvolution: Single
CD4+ T cell stimulatory 15mer peptides were tested for binding to the donor’s HLA-DR molecules using a biochemical HLA class II binding assay, positive interactions
were used to generate peptide-HLA class II tetramers, and these tetramers were used to stain expanded T cells, and the resulting epitopes were eventually validated
by ex vivo ELISpot analysis. CD8+ T cell epitope deconvolution: Single CD8+ T cell stimulatory 15mer peptides were submitted to the NetMHCpan 2.4 predictor
together with the donor’s HLA class I haplotype to identify optimal epitopes and their HLA-restriction elements. These optimal epitopes were subsequently
synthesized and validated by ex vivo peptide-HLA class I tetramer staining.
follow-up analysis could be reduced to 253; 78 representing
CD8+ T cell responses and 218 representing CD4+ T cell
responses (43 of the intersections contained both CD4+ and
CD8+ T cell responses). Peptides corresponding to the 253
intersections were tested individually by ICS; this identified 27
and 31 CD8+ and CD4+ T cell stimulatory 15mer peptides,
respectively (for a detailed listing of these peptides, see Tables 1,2
below). The next steps aimed at identifying the underlying CD8+
and CD4+ T cell epitope(s) and their HLA restriction element(s),
preferably by generating the corresponding tetramer(s), and
validate the epitope(s). For a general outlined of this epitope
discovery scheme, see Figure 2.
CD8+ T Cell Epitope Discovery
Identification and Validation of CD8+ T Cell Epitopes
Exemplified by Donor YF1067
The sequences of the 27 15mer peptides, which stimulated
CD8+ T cell responses in donor YF1067, were submitted, along
with the donor’s HLA-I allotypes (in casu HLA-A∗02:01, -
A∗32:01, -B∗07:02, -B∗40:01, -C∗03:04 and -C∗07:02), to our
webserver NetMHCpan (version 2.4 at http://www.cbs.dtu.dk/
services/NetMHCpan-2.4 was available at the time of this
analysis). In silico, this predictor considered all 26 submer
peptides of 8–11mer length, which could possibly be generated
from a 15mer peptide, and predicted their binding to all six
HLA-I allotypes of donor YF1067, a total of 6 × 26 = 156
submer-HLA-I combinations per 15mer peptide, and returned
a ranked list across all six HLA-I allotypes of the most likely
epitope(s) and their HLA-I restriction element(s). For all 27
CD8+ T cell stimulatory peptides, this amounted to predicting
the binding affinities of 27 × 156 = 4,212 submer-HLA-I
combinations. For each 15mer peptide, submers representing
the top one to three predicted affinities were synthesized and
the stabilities of the corresponding peptide-HLA-I interactions
were measured experimentally (Table 1). Fluorochrome-labeled
tetramers corresponding to the most stable peptide-HLA-I
interactions were generated and used to label relevant CD8+ T
cells. When available, surplus T cells from the initial expansion
cultures were used as a first line of identification of CD8+ T
cell epitopes and their restriction elements, however, ex vivo tests
were always used for the final CD8+ T cell epitope validation,
and for enumerating and characterizing epitope-specific CD8+
T cells. The matrix-identified CD8+ T cell stimulatory 15mer
peptides and the corresponding tetramer-validated optimal
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TABLE 1 | CD8+ T cell epitopes identified in donor YF1067.
CD8+ T cell stimulatory 15-mer peptides Optimal CD8+ T cell epitopes
Ex vivo

















EnvE220−234 GSGGVWREMHHLVEF 3.0 1 0.05 EnvE226−234 REMHHLVEF B*40:01 1.5 0.10 0.8
EnvE224−238 VWREMHHLVEFEPPH 1.6 1 0.05 EnvE226−234 REMHHLVEF B*40:01 1.5 0.10 0.8
EnvEKK468−482 KKTRNMTMSMSMILVGV 0.3 1 0.30 EnvE474−482 SMSMILVGV A*02:01 16.3 0.02 0.1
NS1103−117 PFSRIRDGLQYGWKT 0.5 1 0.40 NS1106−115 RIRDGLQYGW A*32:01 107.9 0.03 0.2
NS1111−125 LQYGWKTWGKNLVFS 3.0 1 0.03 NS1116−124 KTWGKNLVF A*32:01 32.1 0.90 3.7
NS1115−129 WKTWGKNLVFSPGRK 12.2 1 0.03 NS1116−124 KTWGKNLVF A*32:01 32.1 0.90 3.7
NS1351−352/NS2A1−13 TAGEIHAVPFGLVSM 0.7 1 0.01 NS2A1−10 GEIHAVPFGL B*40:01 1.5 0.10 0.4
NS1351−352/NS2A1−13 TAGEIHAVPFGLVSM 0.7 3 0.25 NS2A1−11 GEIHAVPFGLV B*40:01 1.2 0.10 0.3
NS2A95−109 LWSPRERLVLTLGAA 11.6 2 0.03 NS2A97−106 SPRERLVLTL B*07:02 1.8 0.50 4.1
NS2A183−197 FKDTSMQKTIPLVAL 1.1 1 0.80 NS2A187−195 SMQKTIPLV A*02:01 27.3 0.10 0.6
NS2A187−201 SMQKTIPLVALTLTS 0.8 2 0.80 NS2A187−195 SMQKTIPLV A*02:01 27.3 0.10 0.6
NS2BKK111−125 KKPFALLLVLAGWLFHV 3.1 1 0.01 NS2B117−125 VLAGWLFHV A*02:01 28.0 0.20 1.1
NS2B115−129 LLVLAGWLFHVRGAR 2.4 1 0.01 NS2B117−125 VLAGWLFHV A*02:01 28.0 0.20 1.1
NS3117−131 LFKVRNGGEIGAVAL 1.2 1 0.01 NS3124−131 GEIGAVAL B*40:01 3.2 0.10 0.4
NS3121−135 RNGGEIGAVALDYPS 0.0 1 0.01 NS3124−131 GEIGAVAL B*40:01 3.2 0.10 0.4
NS3145−159 RNGEVIGLYGNGILV 1.6 1 1.50 NS3151−159 GLYGNGILV A*02:01 20.0 0.05 0.4
NS3229−243 TRVVLSEMKEAFHGL 2.2 1 0.05 NS3234−243 SEMKEAFHGL B*40:01 1.3 0.20 0.6
NS3233−247 LSEMKEAFHGLDVKF 0.5 1 0.05 NS3234−243 SEMKEAFHGL B*40:01 1.3 0.20 0.6
NS3289−303 DEAHFLDPASIAARG 2.3 1 0.40 NS3293−301 FLDPASIAA A*02:01 9.9 0.10 0.9
NS3293−307 FLDPASIAARGWAAH 1.3 1 0.40 NS3293−301 FLDPASIAA A*02:01 9.9 0.10 0.9
NS3501−515 NMEVRGGMVAPLYGV 0.9 2 0.10 NS3507−515 GMVAPLYGV A*02:01 8.9 0.10 0.3
NS3505−519 RGGMVAPLYGVEGTK 0.5 1 0.10 NS3507−515 GMVAPLYGV A*02:01 8.9 0.10 0.3
NS4A70−84 FFMSPKGISRMSMAM 1.2 1 0.10 NS4A73−82 SPKGISRMSM B*07:02 8.6 0.10 0.8
NS4A18−32 KKGGEAMDTISVFLH 0.5 2 0.40 NS4A21−29 GEAMDTISV B*40:01 1.3 0.02 0.1
NS4BKK209−223 KKEGNTSLLWNGPMAVS 8.1 1 0.13 NS4B214−222 LLWNGPMAV A*02:01 38.2 4.60 41.0
NS4B213−227K SLLWNGPMAVSMTGVK 15.2 1 0.13 NS4B214−222 LLWNGPMAV A*02:01 38.2 4.60 41.0
NS5667−681 DDCVVRPIDDRFGLA 0.9 1 0.15 NS5672−680 RPIDDRFGL B*07:02 6.3 0.30 2.3
NS5671−685 VRPIDDRFGLALSHL 2.5 2 0.15 NS5672−680 RPIDDRFGL B*07:02 6.3 0.30 2.3
NS5671−685 VRPIDDRFGLALSHL 2.5 1 0.03 NS5672−682 RPIDDRFGLAL B*07:02 2.5 0.10 0.9
The 27 CD8+ T cell stimulatory 15mer peptides are given including their sequences and ICS stimulation values. The epitopes eventually identified are given in red. As shown, many
epitopes were found in consecutive 15mer peptides. These 15mer peptides were submitted along with the donors HLA-I haplotype to NetMHCpan 2.4, which returned suggested
epitopes and restriction elements. In most cases, the epitope was found as a top ranking prediction. The stabilities of the suggested peptide-HLA-I complexes were measured and the
corresponding tetramers generated. Finally, these tetramers were used to validate the CD8+ T cell epitopes and to enumerate the responding CD8+ T cells ex vivo.
CD8+ T cell epitopes and their restriction elements are listed
(Table 1). For each of the 27 CD8+ T cell stimulatory 15mer
peptides identified in donor YF1067, one or more CD8+ T cell
epitopes and their HLA-I restriction elements were identified.
Some of the epitopes were present in two consecutive overlapping
15mer peptides and should therefore only be counted as epitopes
once. With this in mind, 19 unique CD8+ T cell epitopes
were recognized by donor YF1067 (7 epitopes restricted by
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HLA-A∗02:01, 2 by HLA-A∗32:01, 4 by HLA-B∗07:02, 6 by HLA-
B∗40:01, and none by HLA-C∗03:04 or -C∗07:02) (Table 1).
CD8+ T cell specific for the 19 unique YFV-derived epitopes
were readily detectable and enumerable ex vivo during the
acute primary response of donor YF1067. The frequencies
of total, as well as activated, tetramer-positive CD8+ T
cells were determined (Table 1). The most frequently and
immunodominant epitope of all, the HLA-A∗02:01-restricted
NS4B214−222 epitope, was recognized by 4.6% of CD8+ T cells
in donor YF1067. The frequencies of CD8T cells recognizing
each of the other 18 epitopes ranged from 0.03 to 0.9%; the total
frequency of CD8+ T cells recognizing the 19 YFV epitopes was
ca. 8%. The YFV vaccine induced a measurable increase in the
overall frequency of activated CD8+ T cells (i.e., CD38+HLA-
DR+CD8+ T cells) (26). In donor YF1067, the YFV vaccine
induced an increase in activated CD8+ T cell from 0.6% pre-
to 7% post-vaccination. Notably, the HLA-A∗02:01-restricted
NS4B214−222- epitope was recognized by 41% of the activated
CD8+ T cells in donor YF1067. The frequencies of activated
CD8+ T cells recognizing each of the other 18 epitopes ranged
from 0.1 to 4.1%. In total, the 19 identified YFV-specific CD8+
T cell epitopes accounted for the majority (ca. 60%) of activated
CD8+ T cells observed during the acute response following
primary YFV vaccination.
Extending CD8+ T Cell Epitope Discovery to 50
Primary YFV Vaccinated Individuals
The CD8+ T cell epitope discovery strategy described above
for donor YF1067 was extended to 50 randomly selected
donors, who were sampled at day 12–21 after vaccination i.e.,
at the peak of a primary anti-YF vaccine response (25, 26).
CD8+ T cell responses specific for 120 different peptide HLA-I
combinations were identified and validated by ex vivo tetramer
staining (for an overview, see Figure 3, and for details, see
Supplementary Table SI). This represented 92 different CD8+
T cell epitopes restricted by 40 different HLA-I molecules; 68,
20 and 4 epitopes were restricted by 1, 2, and 3 different HLA-I
molecules, respectively. The HLA-A, -B and -C allotypes covered
by the 50 donors were, respectively 19, 30, and 20 of which
the majority, 15, 27, and 16, were available to us for tetramer
validation. Thirteen of the 15 different HLA-A allotypes tested
served as restriction elements of 38 different CD8+ T cell peptide
epitopes leading to the presentation of 44 immunogenic peptide-
HLA-A combinations; 26 of the 27 different HLA-B allotypes
tested served as restriction elements of 56 different epitopes
leading to the presentation of 74 immunogenic peptide-HLA-
B combinations; whereas only one of the 16 different HLA-
C allotypes tested served as restriction elements of 2 different
epitopes leading to the presentation of 2 immunogenic peptide-
HLA-C combinations. The average number of CD8+ T cell
epitopes identified per HLA-A and -B allotype, 3.4 and 2.8,
respectively, were not significantly different [P > 50%, Fishers
exact test, two-tailed (GraphPad)].
To the best of our knowledge, 84 of the 92 YF-specific
CD8+ T cell epitopes, and 110 of the 120 epitope-HLA-I
combinations reported here and in previous publications (26, 33),
were first identified as a result of this HFRI project. For the
previously reported epitopes or epitope-HLA-I combinations,
minor adjustments of the already available information could be
made: some had not been tetramer validated before, and others
were also found to be restricted by other, albeit closely related,
HLA-I allotypes than those previously reported. In a few cases,
tetramers representing the exact epitope-HLA-I combinations
previously reported failed to label CD8+ T cells in our donors
despite expressing the appropriate HLA-I allotype (for details see
Supplementary Table SI).
Our in-house peptide repository included 533 YFV-derived
peptides from previous HLA mapping efforts (34). Using the
contemporary NetMHCpan2.4 at %Rank cut-off of 0.5% to select
putative binders from this repository, we generated 90 additional
peptide-HLA-I tetramers (i.e., tetramers that had not already
been prepared in the course of the present HFRI approach).
We included these tetramers in the immunodominance analysis
described below. Nine additional peptide-HLA-I combinations,
which had not been observed previously, were identified; four
representing previously identified epitope presented by an
alternative HLA-I restriction element, and five representing new
YFV-specific CD8+ T cell epitopes (Supplementary Table SII).
Thus, the total number of CD8+ T cell epitopes discovered
and tetramer validated here was 97 of which 92 (or 95%) were
identified by the HFRI approach.
Extending CD8+ T Cell Epitope Discovery to
Additional Donors to Address Immunodominance
We systematically extended the analysis of ex vivo responses to
additional donors expressing relevant HLA-I restriction elements
and evaluated them in terms of prevalence (the frequency
of responders in donors with the HLA-I restriction element
in question) and response magnitude (the average ex vivo
frequency of tetramer positive, activated CD8+ T cells of
the responding donors) Supplementary Tables SI, SII. To allow
for a reasonable assessment of prevalence, the final analysis
included epitopes restricted by HLA-I molecules represented
by at least 5 donors, who had donated blood samples 12–21
days after vaccination. This involved a total of 98 peptide-
HLA combination representing 81 epitopes presented by 24
HLA-I allotypes (Figure 4). Immunodominance was frequently
observed. From an epitope point of view, 25 (or 31%) of
the 81 epitopes had a prevalence of ≥90% and a median
magnitude >0.03%, and 50 (or 62%) had a prevalence of
≥50% and a median magnitude >0.02%. From an HLA point
of view, 16 (or 67%) of the 24 HLA-I molecules presented
at least one epitope with ≥90% prevalence, and all 24 HLA-
I molecules presented at least one epitope with at least 50%
prevalence. In terms of HLA-I coverage and immunodominance,
the vast majority of our cohort, 97, 79, and 43%, carried at
least one, two or three HLA-I allotypes, respectively, which
presented at least one epitope with ≥90% prevalence. A
selection of 10 immunodominant epitopes representing the most
frequent HLA-A and -B allotypes would cover 95% of the
Caucasian population.
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FIGURE 3 | Overview of CD8+ T cell epitopes discovered in 50 primary YFV vaccinated donors. The upper bar indicates the YFV polyprotein. The individual proteins
have been color-coded, and stippled vertical lines are used as further guidance to delineate each protein throughout the rest of the figure. The “all CD8” bar indicates
the positions of each CD8+ T cell stimulatory 15mer peptide relative to the YFV polyprotein. Each 15mer is shown as a frame that horizontally indicates the starting
and ending positions of the 15mer peptide, vertically indicates the number of donors, of the 50 donors tested, who responded to the peptide, and the color-coded is
according to the polyprotein coloring scheme (to enhance the visualization of overlapping peptide sequences, this coloring is translucent). The lower HLA-I
allotype-designated bars indicate the tetramer-validated epitopes and their HLA-I restriction elements (e.g., A*01:01 is shorthand for HLA-A*01:01). Again, the frame
horizontally indicates the starting and ending positions of the epitopes; however, for visual clarity, all frames have the same vertical dimension. The details of each
epitop (epitope sequence, CD8+ T cell stimulation, ex vivo tetramer staining frequency, and response prevalence is given in Supplementary Table SI).
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FIGURE 4 | Prevalence and magnitude of CD8+ T cell responses. To determine the prevalence and the median magnitude of the CD8+ T cell responses toward the
epitopes discovered by the HFRI approach in 50 donors were extended to additional donors expressing the relevant HLA-I restriction elements. Only donors sampled
12–21 days after vaccination were included. The prevalence (gray columns) and the median magnitude of the responses (black diamond) were determined for each
epitope-HLA combination. Only epitope-HLA combinations analyzed in 5 or more donors were included. The epitopes are organized according to restriction elements.
The top figure shows the HLA-A restriction elements; the bottom figure shows the HLA-B and -C restriction elements.
Inhibition of CD8+ T Cell Responses by
Immunodomination in an Outbred Human Population
It has been suggested that immunodominant epitopes can curtail
responses to other epitopes (reviewed in 35). The HLA-A∗02:01
restricted, YFV NS4B214−222-epitope may represent a unique
opportunity to address this in an outbred human population: it
represents an exquisitely dominant CD8+ T cell response as all 93
HLA-A∗02:01-positive donors examined here responded to this
epitope and an average of 29% of all activated CD8+ T cells from
ex vivo blood samples obtained 2–3 weeks after YFV vaccination
were specific for this epitope. It has recently been suggested that
this massive response can be explained by the invariant CDR1α
loop of TRAV12-2 taking part in the recognition of this epitope
(35). In donors, who had donated blood samples at the peak of the
response (12–21 days after vaccination), we examined whether
the presence of HLA-A∗02:01, -A∗01:01, or -A∗03:01, could be
correlated to the strength of CD8+ T cell responses restricted by
other restriction elements, in casu all available HLA-B allotypes.
We included 142 donors, which, respectively, could be split
into 71 and 71 HLA-A∗02:01 positives and negatives, 39 and
103 HLA-A∗01:01 positives and negatives, or 30 and 112 HLA-
A∗03:01 positives and negatives; and used tetramers to examine
the ex vivo frequencies of up to 43 different HLA-B-restricted
responses. In the presence or absence of each of the three HLA-A
restriction elements, the average frequencies of each of the HLA-
B-restricted responses were determined leading to the generation
of up to 43 matched-pairs per HLA-A. The frequencies, or
magnitude, of the HLA-B-restricted responses were significantly
reduced in the presence vs. absence of HLA-A∗02:01 (median
reduction of 0.0432%, P< 0.0001). In contrast, in the presence vs.
absence of HLA-A∗01:01, which have lesser immunodominant
CD8+ T cell responses, there was a smaller and not significant
reduction (median reduction of 0.0165%, P = 0.1353); in the
presence vs. absence of HLA-A∗03:01, which have even fewer
immunodominant CD8+ T cell responses, there was a very small
and non-significant increase (median increase of 0.0041%, P =
0.51) (Wilcoxon Signed-Rank Test, Figure 5). We suggest that
this may be the first demonstration of immunodomination in an
outbred human population.
CD8+ T Cell Epitope Length Distribution and
Recognition of Size Variants
The length of the 97 discovered CD8+ T cell epitopes ranged
from 8 to 11mers with a predominance of 9mers (67 (69%)
9mers, 18 (19%) 10mers, 5 (5%) 11mers, and 7 (7%) 8mers)
(Supplementary Figure S2). This matches well with available
data for peptides eluted of HLA-A and -B molecules (33).
Some of the epitopes were size variants of the same peptide
sequence. In six cases, such size variants were presented by
the same HLA-I restriction element (four cases involving two
size variants each and two cases involving three size variants
each, Supplementary Table SI). We reasoned that CD8+ T cell
recognition of these identically restricted size variants could
either involve cross-recognition of shared epitope structure(s) by
the same TcR(s), or involve recognition of genuinely different
epitope structures by different TcR(s). To evaluate this, tetramers
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FIGURE 5 | A highly immunodominant CD8+ T cell response correlates with a reduction of other CD8+ T cell responses. The NS4B214−222-specific,
HLA-A*02:01-restricted CD8+ T cell response is highly immunodominant. The presence or absence of HLA-A*02:01, HLA-A*01:01 or HLA-A*03:01 in 142 donors
were correlated with the magnitudes (measured as % TMR+, CD8+ T cells) of up to 45 YFV-specific, HLA-B-restricted CD8+ T cell responses. The data was analyzed
by Wilcoxons matched-pair signed rank test (GraphPad Prism 8).
of the different epitope size variants and the relevant HLA
restriction elements were produced with unique fluorochrome
labels and used to determine whether the epitope size variants
were recognized by the same or different T cell populations. In
some cases, distinctly defined and shared subpopulations were
observed (Figures 6A,D,I,J) indicating that one or more unique
shared epitope structures were presented and recognized; in
other cases, we observed shared subpopulations merging with
populations that were single-stained with one of the length-
variant tetramers (Figures 6C,G,H,I); and finally, in some cases,
no shared subpopulations were observed suggesting that the
corresponding length-variants were presented and recognized
as being distinctly different (Figures 6B,E,F). Accommodating
length-variants by extending the peptide-binding groove or by
one or more aa’s bulging out of the groove (34) could affect
the presented epitopes dramatically, whereas accommodating
length-variants by protruding out of the N- or C-terminal
ends of the groove could leave the non-protruding end of
the epitope unaltered. Elucidating the structural basis of these
various recognition modes is beyond the scope of this paper.
Comparison of Strategies of CD8+ T Cell Epitope
Discovery
One of the more frequent HLA allotypes, HLA-B∗07:02, offered
an opportunity to compare the HFRI approach with a strictly
reverse immunology approach. Theoretically, a total of 13,610
peptides of 8–11mer size could be generated from the YFV
proteome. NetMHCpan 2.4 predicted 54 of these as being strong
HLA-B∗07:02 binders at a %Rank of <0.5%. We selected 40 of
those for further examination (Supplementary Table SIII). With
one exception, all of these predicted binders supported HLA-
B∗07:02 tetramer generation, which subsequently were used
to examine ex vivo obtained PBMC’s from at least 16 HLA-
B∗07:02+ donors. Apart from the epitopes that had already
been described (Supplementary Tables SI, SII), no additional
HLA-B∗07:02-restricted CD8+ T cell epitopes were identified.
Thus, a final count can be made: combining the HFRI and a
strictly reverse immunology approach, a total of 10 unique HLA-
B∗07:02-restricted CD8+ T cell epitopes were found; the HFRI
strategy identified nine of these, whereas the reverse immunology
strategy identified eight; seven (70%) of these epitopes were
shared. Assuming that the number of true positive HLA-B∗07:02
epitopes is ten, then both strategies were sensitive (correctly
identifying 80–90% of the 10 epitopes) and at the same time very
specific (correctly rejecting 99.6% of the 13,600 non-epitopes);
the HFRI approach being slightly more sensitive and specific
than the reverse immunology approach. The major performance
difference between the two strategies arose from the lower false
discovery rate (FDR) where the HFRI screening strategy required
13 peptides to identify nine of the ten epitopes found (a FDR
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FIGURE 6 | CD8+ T cells double stained with combinations of tetramers of size-variants epitopes. (A–J) PBMCs were in vitro expanded for 8 days with relevant
15-mers peptides, and subsequently stained with pairs of tetramers representing size-variants epitopes as indicated in the figure (one member of each pair was
PE-labeled and the other was APC-labeled) and analyzed by flow cytometry gating for CD3+CD8+T cells.
of 17%; albeit some of these apparently false positive peptides
were eventually identified as epitopes restricted by other HLA-I
restricting elements expressed by the donors suggesting that the
true false discovery rate of the HFRI approach was even smaller),
whereas the reverse immunology approach required 54 peptides
to identify eight of the ten epitopes suggesting a false discovery
rate of 85%.
In conclusion, the present HFRI approach ranks epitope at
the very top of the list of candidates while decimating the
false discovery rate (further comparisons of HFRI vs. reverse
immunology is described in the Discussion and detailed in
Supplementary Results and Discussion).
Efficiencies of CD8+ T Cell Epitope Predictors
The unbiased nature of our cohort of 120 different HFRI-
identified peptide HLA-I combinations covering 40 HLA-I
restriction elements provided an opportunity to evaluate the
performance and discriminatory power of various prediction
methods such as the authoritative NetMHCpan [both the
contemporary version 2.4 (36) and the most recent version 4.0
(37) trained on both eluted ligands (EL) and peptide binding
affinity (BA)], and the recent MHCFlurry (38) (trained either
only on BA data or on both EL and BA data) (38) and
MixMHCpred (trained only on EL data) (39). In addition to
these peptide-HLA-I affinity predictors, we also included a
stability predictor, NetMHCStabpan 1.0 (40). For each of these
methods, predictions scores of all 13,610 peptides of length 8–
11 aa that could be generated from the 3,411 aa YFV proteome
were predicted for the relevant HLAs (using %Rank scores
allowing comparisons across HLA allotypes and predictors as
read-outs). Subsequently, a Receiver Operating Characteristics
(ROC) analysis was performed and the Area Under the Curve
(AUC) was determined. A non-discriminatory predictor has an
AUC of 0.5, whereas a perfectly discriminating predictor has
an AUC of 1.0. Applied to this unbiased and validated set
of epitopes, all of these predictors gave highly discriminatory
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AUC’s of 0.98743 to 0.99797 (Supplementary Figure S3). These
impressive AUC’s are heavily influenced by the many non-
immunogenic peptides being correctly rejected; however, this
may still leave considerable room for false positive discovery
rates (FDR). In this case, a more FDR-averse way to visualize
the performance is to use the Frank score, which is the number
of false positive predictions (FP) relative to the total number
of peptides (N) that can be generated from the source protein
(i.e., Frank = FP/N). A Frank score of 0 indicates a “perfect
prediction” where a true epitope receives the highest prediction
value of all peptides within the source protein and avoids any
false positive predictions, whereas a Frank score of 0.5 indicates
a random prediction where half of the predictions are false
positives. Frank values were calculated for each epitope-HLA pair
and predictor (Supplementary Figure S2). The best predictors
were NetMHCpan 4.0 EL andMixMHCpred, which, respectively,
scored 21 and 20 “perfect” predictions, obtained an average
Frank score of 0.001875 and 0.003809, and a median Frank
score of 0.000405 and 0.000588, respectively. The median, being
a more “outlier-resistant” measure, would, respectively, indicate
that the NetMHCpan 4.0 EL and MixMHCpred methods would
place 6 and 8 false-positive non-epitopes ahead of each epitope,
corresponding to a false discovery rate of 85 and 89%. These
numbers should be appreciated in the context of a random
predictor, which would yield a FDR of 99%, and a perfect
predictor which would yield an FDR of ca. 50% [assuming that
only 50% of HLA-presented peptides are immunogenic (2)]. In
line with earlier work (41), comparing the predictive power of
the various predictors in terms of the Frank values, NetMHCpan
4.0 EL was found to significantly outperform all other predictors
(P < 0.02 in all cases, Wilcoxon matched-pairs signed rank test)
(Supplementary Figure S2).
CD4+ T Cell Epitope Discovery
Identification and Validation of CD4+ T Cell Epitopes
(Exemplified by Donor YF1067)
In donor YF1067, the ICS-based screening analysis identified
31 15mer peptides as stimulating CD4+ T cell responses. At
face value, these 15mer peptide sequences qualified as CD4+ T
cell epitopes (the IEDB epitope curation manual 2.0 defines a
CD4+ T cell epitope of 15 residues or less in length as an “exact
epitope”). To identify the underlying HLA class II restriction
elements, the binding of each of the 31 15mer peptides to each
of the HLA-DR molecules of donor YF1067 (in casu HLA-
DRB1∗13:02, -DRB1∗15:01, -DRB3∗03:01 and -DRB5∗01:01) was
tested in a biochemical binding affinity assay (42). Nine (28%),
eleven (34%), four (13%) and four (13%) of the epitopes bound
with an affinity better than 50 nM to one, two, three and four of
the donor’s HLA-DR molecules, respectively (Table 2), whereas
three (9%) bound to none of them. Secondly, we generated
tetramers for 50 of the (9×1 + 11×2 + 4×3 + 4×4) = 59
strongly interacting peptide-HLA combinations and used these
to label in vitro expanded CD4+ T cells from donor YF1067.
Twenty-two of the 50 tetramers successfully identified CD4+ T
cell epitopes and their HLA-DR-restriction elements (Figure 7).
The final validation and enumeration of specific CD4+ T cell
was performed by an ex vivo IFNγ ELISpot analysis (Table 2).
In one case, the same epitope was presented by two different
HLA-DRB allotypes and should therefore only be counted as
epitope once. Thus, 21 of the 31 different HLA-DR-restricted
CD4+ T cell epitopes observed in donor YF1067 were identified
at the tetramer level; the remaining eleven epitopes were not
resolved. The latter could potentially be explained as being
restricted by HLA-DQ or DP molecules; something that could
not be readily addressed by our tetramer capabilities at the time;
albeit, in one case, we successfully generated a NS4B233−247-
DPA1∗01:03-DPB1∗04:01 tetramer and identified an HLA-DP-
restricted epitope.
Although 19 of the 32 CD4+ T cell stimulatory peptides
bound to more than one of the four HLA-DR allotypes of donor
YF1067, there was only one epitope that exploited more than
one of the available HLA-DR allotypes as restriction element: the
NS5551−565 epitope, which was recognized by CD4+ T cells in the
context of both HLA-DRB1∗15:01 and HLA-DRB5∗01:01. That
this was not a case of TcR cross-recognition was shown by double
staining with the two tetramers showing two distinctly different
CD4+ T cell populations recognizing the NS5551−565-epitope
presented by either HLA-DRB1∗15:01 or HLA-DRB5∗01:01 (see
section Recognizing the Same CD4+ T Cell Epitope Presented
by Two to Three Different HLA-DR Allotypes below). Thus, in
donor YF1067, a total of 31 CD4+ T cell epitopes were identified;
22 of these could be HLA-DR or -DP tetramer validated.
Extending CD4+ T Cell Epitope Discovery to 50
Primary YFV Vaccinated Individuals
The CD4+ T cell epitope discovery strategy was extended to
the same 50 donors used for CD8+ T cell epitope discovery.
A total of 192 CD4+ T cell stimulatory 15mer epitopes were
identified (for an overview, see Figure 8 “All CD4”, and for
details, see Supplementary Table SIV). Some of these epitopes
were frequently recognized. Thus, the single most recognized
CD4+ T cell epitope, EnvE44−58, was recognized in 22 (71%) of
31 tetramer-tested donors tested, and another 12 epitopes were
recognized in 10–16 (32–52%) of 31 donors. However, most of
the 192 epitopes were much less frequently recognized; in fact, 76
of the peptides were recognized in only one (3%) of the 31 donors.
We suggest that the strongest and most immunodominant CD4+
T cell epitopes have been found.
An important objective was to identify and validate
the HLA-DR restriction element(s) used to present these
epitopes (for an overview, see Figure 8, and for details, see
Supplementary Table SV). We have evaluated the restriction
elements for 74 of the 192 epitopes. For each epitope, the most
likely HLA-DR restricting element was selected based on its
affinity to one or more of the HLA-DR allotypes available to
the donor. Guidance was also obtained from which HLA-DR
allotypes were shared amongst the epitope-responding donors.
In some cases, more than one strong binding HLA-DR allotype
and/or more than one shared HLA-DR allotype were found
highlighting that multiple HLA-DR allotypes would have to be
considered as potential restriction elements.
In total, 152 peptide-HLA-DR tetramers were generated
and used to validate the CD4+ T cell epitopes. Of these, 64
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TABLE 2 | CD4+ T cell epitopes identified in donor YF1067.
CD4+ T cell stimulatory 15-mer peptides Measured affinity (nM)
In vitro Ex vivo Tetramer

















CapsidC17−31 RRGVRSLSNKIKQKT 0.7 125 DRB5*01:01 31 212 32 3.5
CapsidC73−−87 DPRQGLAVLRKVKRV 3.1 35 DRB1*13:02 5 198 292 12.5
prM92−−106 DLPTHENHGLKTRQE 1.8 241 NA 185 NB 2725 529
EnvE44−−58 SLETVAIDRPAEVRK 6.4 367 DRB3*03:01 1643 NB 21 NB
EnvE56−−70 VRKVCYNAVLTHVKI 1.3 106 DRB5*01:01 35 NB 5 4
EnvE60−−74 CYNAVLTHVKINDKC 0.7 86 DRB5*01:01 98 1248 NB 8.5
EnvE128−−142 FEVDQTKIQYVIRAQ 1.1 163 NA 235 302 1115 219
EnvE272−−286 NLYKLHGGHVSCRVK 1.3 42 DRB1*13:02 9 NB 21 4
EnvE340−−354 LTAAINKGILVTVNP 3.4 80 DRB3*03:01 1590 NB 2 NB
EnvEKK448−−462 KKGLNWITKVIMGAVLI 0.8 99 NA 46 NB 14 NB
EnvE460−−47K4 VLIWVGINTRNMTMSK 1.0 32 Not DRB 19 3089 70 3
NS1111−−125 LQYGWKTWGKNLVFS 1.3 75 DRB1*13:02 9 52 202 5
NS1327−−341 DGCWYPMEIRPRKTH 2.3 125 DRB5*01:01 25 318 264 2
NS2A87−−101 LIGFGLRTLWSPRER 0.7 39 Not DRB 6 NB 334 19
NS3145−−159 RNGEVIGLYGNGILV 3.3 153 Not DRB 1443 7.5 193 NB
NS3149−−163 VIGLYGNGILVGDNS 2.2 107 DRB1*15:01 NB 14 690 NB
NS3209−−223 LPQILAECARRRLRT 7.0 129 Not DRB 6 7 21 2
NS3293−−307 FLDPASIAARGWAAH 1.7 194 Not DRB 306 575 251 46
NS3393−−407 KTFEREYPTIKQKKP 3.4 53 DRB5*01:01 794 2286 NB 2
NS3537−−551 FRELVRNCDLPVWLS 2.4 12 DRB3*03:01 90 21 5 91
NS4B41−−55K TVYVGIVTMLSPMLHK 1.4 114 Not DRB 9 23 11 2
NS4B81−−95K DKGIPFMKMNISVIMK 0.9 295 DRB3*03:01 84 61 3 18
NS4B146−−159 KNPVVDGNPTVDIEE 2.9 125 DRB3*03:01 NB NB 7 NB
NS4B149−−163 VDGNPTVDIEEAPEM 0.8 8 DRB3*03:01 NB NB 22 NB
NS4BKK169−−183 KKKKLALYLLLALSLAS 0.6 135 Not DRB NB 80 133 199
NS4B233−−247K YAFVGVMYNLWKMKTK 1.1 230 DPA1*01:03-
DPB1*04:01
9 94 NA 2.5
NS559−−73 TAKLRWFHERGYVKL 2.6 39 DRB5*01:01 10 12 1091 3.5
NS5371−−385 TRKIMKVVNRWLFRH 2.1 111 DRB1*15:01 11 7 11 10
NS5399−−413 EFIAKVRSHAAIGAY 0.8 136 DRB1*15:01 6 2 31 5
NS5551−−565 EQEILNYMSPHHKKL 4.2 122 DRB1*15:01 &
DRB5*01:01
29 29 47 2
NS5555−569 LNYMSPHHKKLAQAV 1.1 22 DRB5*01:01 6 461 1124 2
The 31 CD4+ T cell stimulatory 15mer peptides are given including their sequences and ICS stimulation values. Overlaps between two consecutive peptides are given in red. The
binding affinity of the 15mer peptides to the four HLA-DRB1 allotypes of donor YF1067 were measured. Tetramers corresponding to the strongest binders were generated. The resulting
tetramers were used to stain and analyze expanded CD4+ T cells by flow cytometry gating on CD3+ CD4+ T cells. In 21 cases, staining with a HLA-DR tetramer was demonstrated
(Figure 7). Note, that no HLA-DR-restricted CD4+ T cell responses were found for the NS4B (233-247) epitope, YAFVGVMYNLWKMKT. Eventually, it was found to be a DPA1*01:03-
DPB1*04:01 binder, the corresponding tetramer was generated, and CD4+ T cell staining could be demonstrated (Figure 7). Finally, an ex vivo Elispot assay was performed to validate
the CD4+ T cell epitopes.
tetramers were tested positive for CD4+ T cell staining in
one or more donors. This covered 50 CD4+ T cell peptide
epitopes restricted by 13 different HLA-DR molecules (some
epitopes were presented by more than one HLA-DR allotype)
and one HLA-DP molecule. For 17 of the 50 epitopes, the
HLA-DR molecules available to us for tetramer generation
did only partially cover the HLA-DR molecules observed in
one or more of the responding donors. As an example, the
most frequently recognized epitope, EnvE44−58, was found in
23 donors (Supplementary Tables SIV, SV). Using appropriate
tetramers, two restriction elements, HLA- DRB1∗03:01 and -
DRB3∗03:01, were identified, however, four of the EnvE44−58
responding donors expressed neither the DRB1∗03:01 nor the
DRB3∗03:01. This suggested that one or more additional, not
yet identified, restriction element(s) existed for this epitope;
something that could apply to more of the 17 epitopes.
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FIGURE 7 | CD4+ T cell epitopes in donor YF1067. PBMC’s from donor YF-1067 were expanded using the stimulatory 15mer peptides identified. For each peptide,
a biochemical HLA class II binding assay was used to identify which of donor YF1067’s HLA-II molecules could bind the peptide and therefore could serve as
restriction elements. Productively interacting peptide-HLA-II combinations were used to design and generate peptide-HLA class II tetramers. The resulting tetramers
were used to stain and analyze expanded CD4+ T cells by flow cytometry gating on CD3+ T cells. Note, that the selective HLA class II tetramer staining of CD4+, not
CD8+, T cells is a demonstration of the specificity of the tetramer staining. The identities of the epitopes and their restricting HLA-II elements are indicated.
Recognizing the Same CD4+ T Cell Epitope
Presented by Two to Three Different HLA-DR
Allotypes
Some of the 15mer peptides could stimulate CD4+ T cell
responses restricted by two or three different HLA-DR restriction
elements (Supplementary Table SV). No donor happened to
possess three appropriate HLA-DR molecules, but some did
possess two and could generate appropriate CD4+ T cell
response restricted by both of these restriction elements.
In these cases, staining CD4+ T cells with two uniquely
labeled tetramers, representing either of the two restriction
elements, allowed us to address whether the same epitope
presented by two different restriction elements were recognized
by the same, or by distinctly different, CD4+ T cells.
When presented by different HLA-DR molecules, five of the
eight epitopes [NS5551−565 presented by HLA-DRB1∗15:01
and -DRB5∗01:01 (26 amino acid differences); NS3285−299,
NS3281−295, and EnvE44−58 presented by HLA-DRB1∗03:01 and
-DRB3∗03:01 (13 amino acid differences); and Capsid81−95
presented by HLA-DRB1∗07:01 and -DRB1∗11:01 (25 amino
acid differences)] engaged distinctly different CD4+ T cell
populations (Figures 9A–E). The remaining three epitopes were
presented by the closely related HLA-DR allotypes (HLA-
DRB1∗13:01 and -DRB1∗13:02 (one amino acid difference, a
V86G, a part of the peptide binding site interacting with P1
of the core sequence), NS357−71, NS559−73, and NS1111−125,
showed various degrees of cross-recognition. The NS357−71
peptide presented by HLA-DRB1∗13:01 and -DRB1∗13:02 is
mostly recognized by separate T cell populations; only a small
population recognized the peptide presented by both molecules
(Figure 9F). For peptides, NS559−73 and NS1111−125 about half
of the T cells recognizing the peptides presented by HLA-
DRB1∗13:01 cross-recognized the peptides presented by HLA-
DRB1∗13:02, with none or a very small T cell population
recognizing the peptides presented only by HLA-DRB1∗13:02
(Figures 9G,H). We speculate that a peptide presented by two
restricting HLA-DR molecules with only a few polymorphic
amino acid differences may be cross-recognized by some, but
not necessarily all, CD4+ T cells of appropriate specificity,
whereas, presentation by two restricting HLA-DRmolecules with
many polymorphic amino acid differences are more likely to be
recognized as being distinctly different.
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FIGURE 8 | Overview of CD4+ T cell epitopes discovered in 50 primary YFV vaccinated donors. Similar to Figure 3, the color-coded upper bar indicates the YFV
polyprotein. The “all CD4” bar indicates the positions of each of the 192 CD4+ T cell stimulatory 15mer peptides and their prevalence. The lower HLA-II
allotype-designated bars indicate the tetramer-validated epitopes and their HLA-II restriction elements. The details of each epitope (epitope sequence, CD4+ T cell
stimulation, ex vivo tetramer staining frequency, and response prevalence is given in Supplementary Table SV).
The Recognition of Overlapping CD4+ T Cell
Epitopes Presented by the Same HLA-DR Allotype
Expands the Diversity of CD4+ T Cell Specificities
In 16 cases, two consecutive overlapping 15mer peptides
stimulated CD4+ T cell responses restricted by the same
HLA-DR restriction element. If the two peptides of such an
overlapping 15mer peptide pair were presented through two
different core regions, one for each, then the two neighboring
epitopes should be perceived as being distinctly different and
should be recognized by two disparate CD4+ T cell populations.
Alternatively, if the two peptides were presented through the
exact same core region, then the two neighboring epitopes could
potentially be perceived as being identical and be recognized
by the same CD4+ T cell populations. To examine this, CD4+
T cells were double-stained with HLA-DR tetramers, which
had been prepared with each of the overlapping peptides of
a 15mer pair and labeled with a unique fluorochrome. We
analyzed 10 such pairs and found a wide variety of staining
patterns. In no case did two peptides of an overlapping
pair engage two distinctly different CD4+ T cell populations;
rather, in all cases observed, the two peptides engaged at
least some shared CD4+ T cell populations suggesting usage
of shared core regions. In most cases, a plethora of shared,
yet subtly different, CD4+ T cell populations were observed
(Figure 10). By way of examples, tetramers representing
the overlapping HLA-DRB1∗01:01-restricted 15mer peptides,
CapC49−63 and CapC53−67, revealed multiple distinct CD4+ T
cell subpopulations, which recognized one, the other, or both
tetramers at various efficiencies (Figure 10A); whereas tetramers
representing the overlapping HLA-DRB1∗01:01-restricted 15mer
peptides, NS5471−485 and NS5475−489, revealed almost exclusively
CD4+ T cell subpopulations recognizing both tetramers,
albeit clearly comprising multiple distinct subpopulations
(Figure 10B). We argue that this phenomenon increases and
diversifies CD4+ T cell responses.
Distribution of YFV-Specific CD8+ and
CD4+ T Cell Epitopes
Apart from two small proteins, the 20 aa ER anchor and the
164 aa prM proteins, all YFV proteins contained both CD8+
and CD4+ T cell epitopes. On average, the frequencies of
CD8+ and CD4+ T cell epitopes were ca. 3 and 6 per 100 aa,
respectively (Table 3). Notably, the CD8T cell epitopes, which
have been tetramer mapped exhaustively, exhibited stretches
of overlapping epitopes restricted by several different HLA
class I molecules: twelve stretches encompassing two epitopes,
five stretches encompassing three epitopes, and three larger
hot-spots areas encompassing four to six epitopes, many of
which were presented by several different HLA molecules. Thus,
the frequently recognized EnvE200−240 sequence comprised six
peptide epitopes and ten HLA-restriction elements giving a total
of twelve epitope-HLA combinations (Figure 11). These three
hot-spot regions accounted for about 15 of the 97 (15%) CD8+
T cell epitopes identified, and encompassed 15 HLA-I restriction
Frontiers in Immunology | www.frontiersin.org 15 August 2020 | Volume 11 | Article 1836
Stryhn et al. Comprehensive T Cell Epitope Discovery
FIGURE 9 | Double staining of CD4+ T cells with tetramers representing the same epitope presented by two different HLA-II molecules. (A–H) PBMC’s from donors
recognizing the same epitope presented by two of the HLA-DR molecules of the donors were expanded using the relevant 15mer peptides. The cells were
subsequently double stained with the indicated two tetramers representing peptide-HLA-DR combinations labeled with PE or APC, respectively, and analyzed by flow
cytometry gating on CD3+CD4+ T cells. The PE-labeled tetramers are shown on the x-axis and the APC-labeled tetramers are shown on the y-axis.
FIGURE 10 | Double staining of CD4+ T cells with tetramers representing two overlapping 15-mer epitopes presented by the same HLA-II molecule. (A–J) PBMC’s
from donors recognizing two overlapping 15mer epitopes presented by the same HLA-DR molecule were expanded using the relevant 15mer peptides. The cells were
subsequently double stained with the indicated tetramers representing two overlapping peptide-HLA-DR combinations labeled with PE and APC, respectively, and
analyzed by flow cytometry gating on CD3+CD4+ T cells. The PE-labeled tetramers are shown on the x-axis and the APC-labeled tetramers are shown on the y-axis.
elements covering ca. 77% of the Caucasian race. Although the
YF protein was generated as one long precursor polyprotein,
no epitopes were found in any of the overlaps between the
different processed proteins. No epitopes were found in any
of the peptides representing products of alternative translation
initiation codons.
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DISCUSSION
In order to understand the complexity of the human T-cell
response to a circulating pathogen, and its potential impact on
population dynamics of both pathogen and host, knowing a
wide range of epitopes relevant for T-cell/pathogen interplay
is essential. However, identifying the exact epitope sequence
and the exact HLA allotype involved in T cell recognition of a
specific pathogen is a demanding challenge. Over the years, a
plethora of methods have been used to identify T cell epitopes.
There are two major and principally different approaches of
T cell epitope discovery. The “forward immunology” approach
(28, 29) uses specific T cell responses as a starting point
to search for the underlying T cell epitope and its MHC
restriction, whereas the “reverse immunology” approach (30,
31) uses predictions (e.g., of peptide-MHC interactions) to
suggest possible T cell epitopes and then screen them for their
ability to stimulate specific T cell responses [reviewed in (9, 43,
TABLE 3 | Overview of the number of the total number of YFV-specific CD4+ and




















Capsid C 101 12 (11.9) 2 (2.0) 14(13.9)
prM 164 14 (8.5) 0 (0.0) 14 (8.5)
Envelope 493 29 (5.9) 15 (3.0) 44 (8.9)
ER anchor 20 0 (0) 2 (10.0) 2 (10.0)
NS1 352 18 (5.1) 12 (3.4) 30 (8.5)
NS2A 224 13 (5.8) 8 (3.6) 21 (9.4)
NS2B 130 4 (3.1) 3 (2.3) 7 (5.4)
NS3 623 47 (7.5) 19 (3.0) 66 (10.6)
NS4A 149 2 (1.3) 6 (4.0) 8 (5.4)
NS4B 250 21 (8.4) 5 (2.0) 26 (10.4)
NS5 905 31 (3.4) 25 (2.8) 56 (6.2)
Total YF
polypeptide
3,411 191 (5.6) 97 (2.8) 288 (8.4)
The frequencies of epitopes per 100 aa are also given.
44)]. The experimental procedures involved in both of these
epitope discovery modes tend to involve slow, low throughput,
cumbersome and expensive processes [e.g., expression cloning
of antigen libraries and/or HLA genes (28, 45–48), synthesis of
peptide libraries etc.]. In contrast, the bioinformatics component
of a reverse immunology approach offers a process that is fast,
of high capacity and throughput, yet very easy and inexpensive;
a process, which is well-suited to support systematic analyses
of genomic and proteomic information (3, 4, 9, 30). It is not
surprising that reverse immunology has become the preferred
approach to T cell discovery. The need for high speed and
capacity is of obvious importance in emerging infectious diseases
(including bioterrorism), and even more so in personalized
cancer immunotherapy where fast and high-throughputmethods
are essential for the selection of relevant and safe cancer
neoepitopes in real time. Current peptide-MHC predictors are
highly sensitive and specific [96.5 and 98.5%, respectively (16)].
However, despite continued improvements of these predictors,
the false discovery rate (FDR) is very high (8, 10, 18); something
that compromises the successful inclusion of one, or preferably
more, T cell epitopes in cancer immunotherapy even if these
encompass up to 10–20 predicted epitopes (20, 21). Reducing the
FDR while maintaining the sensitivity will be needed if reverse
immunology in the future should fully support neoantigen
discovery and secure timely, personalized immunotherapy of
cancer (19).
Indeed, most of the larger CD8+ and CD4+ T cell
epitope submissions to the IEDB have been identified by
“reverse immunology.” Thus, Sette and coworkers used “reverse
immunology” to identify Dengue virus-specific T cell epitopes
and have, as of July 2019, contributed with the single largest
submissions of CD8+ and CD4+ T cell epitopes (IEDB reference
ID 1027503, 1031475, and 1031301). In contrast, the “forward
immunology” approach has fallen relatively into disuse. An
innovative approach pioneered by Koelle and co-workers,
which has resulted in larger IEDB submissions of CD8+ and
CD4+ T cell epitopes (e.g., IEDB reference ID 1021375), have
used a “forward” component where co-transfecting panels of
APC with cDNA encoding antigen and HLA class I or II,
each APC representing a single antigen and a single HLA
restriction element, were used to interrogate CD4+ and CD4+
T cell responses of virus infected donors (48). The “forward”
component of this approach identified intact immunogenic
FIGURE 11 | An example of a CD8+ T cell epitope hot spot: the EnvE200−240 region. The 40 amino acid sequence EnvE200−240 included 6 different CD8+ T cell
epitopes presented by 10 different HLA-I molecules – in total 12 different peptide-HLA-I combinations. The boxed sequences represent the epitopes that are
presented and recognized by the restriction elements indicated at the top or bottom of the box. A box and its indicated restriction element is identically colored.
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protein antigens and their restriction element(s); however, for
the epitope discovery part of this work, the entire antigen was
subjected to a “reverse” component predicting the epitope(s) and
its HLA restriction element(s). Another innovative approach,
Tetramer Guided Epitope Mapping (TGEM), pioneered by
Kwok and James, which has resulted in large CD4+ T cell
epitope submissions [IEDB references ID 1026930 (49), 1013360,
1016040, and 1020783], have also used a “forward” component.
Longer overlapping peptides representing entire antigens were
offered to single HLA class II molecules and the resulting
peptide-HLA class II complexes were multimerized and the
ensuing tetramers used to interrogate CD4+ T cell responses of
appropriate donors. Using shorter overlapping peptides suitable
as CD8+ T cell epitopes, Maeurer and coworkers established
a tetramer-based approach for CD8+ T cell epitope discovery,
which also resulted in larger IEDB submissions [IEDB ID
1026840 (50)]. This latter approach would obviously be very
peptide intensive if every relevant peptide was to be tested in
that way (e.g., the Yellow Fever proteome would require 13610
peptides to represent all possible 8–11mer peptides).
Here, we have generated a “hybrid forward-reverse
immunology” (HFRI) approach capable of doing concurrent
CD8+ and CD4+ T cell epitope discovery and demonstrated
that it can perform large-scale epitope discovery and at the same
time decimate the false positive discovery rate. For the initial
“forward immunology” screen, we used an overlapping peptide
library of 850 15mer peptides overlapping by 11 aa, which
represented the entire 3,411 aa Yellow Fever Virus proteome, to
stimulate PBMC’s obtained ex vivo from primary Yellow Fever
Virus vaccinees at the peak of the resulting T cell response.
Since 15mer peptides are further processed during in vitro
ICS and/or ELIspot assays, this peptide library represented all
possible YFV-specific CD4+ and CD8+ T cell epitopes of up to
12 aa in length; some, but not all, epitopes of 13–15 aa in length;
and no epitopes of a length longer than 15 aa. Distributing this
peptide library into 4 matrices, the initial screening effort could
be reduced to testing ca. 120 peptide pools for their ability to
stimulate T cell responses preferably by ICS analysis. The matrix
design subsequently allowed us to home in on the individual T
cell stimulatory peptides.
Following the “forward immunology” screening, a “reverse
immunology” approach was applied to all the 15mer peptides
containing CD8+ T cell epitopes. In silico, the affinities of
all possible 8–11mer peptides that could be generated from
the 15mer were predicted in the context of up to 6 different
HLA-A, -B and -C allotypes per individual. This reduced the
number of potential peptide-HLA-A, -B or -C combinations
from 156 per stimulatory 15mer peptide to typically one to three
combinations. The most likely peptide binders were synthesized
and used to generate appropriate peptide-HLA-I tetramer(s),
which subsequently were used to validate CD8+ T cell epitope(s).
For the vast majority of T cell stimulatory 15mer peptides, at
least one epitope was identified per 15mer peptide. Once the
stimulatory 15mer peptides had been identified, predicting the
exact epitope and its restriction element was a highly efficient
process; typically, the epitopes ranked first, second or third
amongst the many potential epitope-HLA combinations. As
a cost-saving measure, if the predictions clearly discriminated
between the candidates, a consecutive process was applied
whereby the top peptide(s) were synthesized and tested before
any next tier peptides were synthesized and tested. This HFRI
approach was extended to 50 primary YFV vaccinees, where
it identified and tetramer-validated 92 CD8+ T cell epitopes
(predominantly of size 9–10mer, range 8–11mer) covering 40
HLA-I allotypes (representing a total of 120 peptide-HLA-I
combinations). Before this work, the IEDB had registered ten
YFV-specific CD8+ T cell epitopes as being “exact epitopes” (i.e.,
length from 7 to 11 aa) and restricted by an HLA allotype defined
at high (4-digit) resolution; however, none of them were tetramer
validated. Four of the ten already registered YFV-specific, CD8+
T cell epitopes were included in the 92 epitopes identified here.
Thus, the present approach identified and validated 92 – 4 = 88
new, or ca. 90% of all currently known, YFV-specific, CD8+ T
cell epitopes. The total number of exact CD8+ T cell epitopes
with high resolution HLA-I restriction, which are currently
registered in the IEDB is 2,612 of which 1,101 have been tetramer
validated (extracted from the IEDB, July 2019). Thus, this study
accounts for >8% of these tetramer-validated human CD8+ T
cell epitopes.
To evaluate the prevalence of the different YFV-specific CD8+
T cell immune responses, the tetramer analysis was extended to
additional vaccinees with the appropriate HLA-I allotypes. Many
epitopes were frequently observed (i.e., were highly prevalent)
in vaccinees with the appropriate HLA allotype. Thus; 25 (ca.
31%) and 50 (ca. 62%) of 81 CD8+ T cell epitopes were
observed in ≥90 and ≥50%, respectively, of vaccinees with the
appropriate HLA-I allele. Conversely, 18 (ca. 75%) of 24 HLA-
I allotypes presented at least one CD8+ T cell epitope with
a prevalence of ≥90%. Thus, the HFRI approach identified
a cohort of immunodominant Yellow Fever-derived peptides,
which could be of broad diagnostic and therapeutic interest.
Large-scale T cell epitope discovery could also address more
fundamental issues in immunobiology. Pertinent examples of
phenomena that are poorly understood include the closely
related immunodominance (that the immune response is focused
on just a few of the many available determinants expressed
by a pathogen) and immunodomination (that the immune
response of one specificity can suppress the response of another
specificity). Not surprising, these phenomena are closely related
to antigen processing and presentation including MHC and
T cell repertoire (51). The vast majority of experimental data
on immunodominance and immunodomination emanates from
studies involving inbreed mice. Few studies in humans address
immunodominance [e.g., (52)]; to the best of our knowledge
none involve immunodomination. The latter is particularly
difficult to address in an outbreed system like the human where
the extremely diverse HLA creates context dependent effects that
confounds attempts to address immunodomination. Assuming
that the context-dependent effects HLA could even out in
larger donor cohorts, we exploited the size of our study to ask
whether the presence of HLA-A∗02:01, which restricts a strongly
immunodominant, NS4B214−222-specific T cell response, would
correlate with a reduction of responses restricted by other
HLA allotypes. Indeed, under these conditions, we could
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demonstrate such a correlation in the presence of HLA-A∗02:01,
but not in the presence of HLA-A∗01:01 or -A∗03:01. Note
that the HLA-A∗01:01 or -A∗03:01 allotypes themselves featured
a hierarchy of immunodominant T cell responses i.e., they
are valid HLA restricting elements. This may be the first
demonstration of primary anti-virus responses being subjected
to immunodomination in humans. A further analysis of the
mechanism of behind these phenomena is beyond the scope of
this paper.
HLA-C restricted, CD8+ T cell epitopes were scarcely
represented (<3%) in the IEDB; something that potentially
could be explained by HLA-C being insufficiently investigated.
A priori, we expected that the unbiased nature of our approach
would reveal several HLA-C restricted CD8+ T cell epitopes,
however, we only found one case of a strong and highly prevalent
CD8+ T cell response, which could not be explained by any
of the HLA-A or -B allotypes available to the responding
donors. Instead, a strongly predicted binding to a shared
HLA-C allotype amongst the responding donors suggested an
HLA-C∗06:02 restricted response. Eventually, twoHLA-C∗06:02-
restricted epitope length variants; NS3207−213 (TRRFLPQIL) and
NS3208−213 (RRFLPQIL), were tetramer validated. These were
the only HLA-C restricted CD8+ T cell epitope identified; all
other identified CD8+ T cell epitopes were validated as being
either HLA-A or -B restricted. HLA-C is less polymorphic and is
known to be expressed at a lower level than HLA-A and -B (53–
56); something that has been correlated with reduced cytotoxic
T lymphocyte responses (57, 58). In the case of the HLA-
C∗06:02-restricted NS3207−213 (TRRFLPQIL) epitope identified
here, any reduced expression level of HLA-C∗06:02 might have
been compensated by the very strong predicted binding affinity
for NS3207−213. Although weaker HLA-C-restricted CD8+ T
cell responses may have been missed, we would argue that it
is unlikely that we have missed strong and prevalent HLA-C
restricted CD8+ T cell epitopes. Thus, we suggest that the paucity
of strong HLA-C restricted CD8+ T cell responses, at least in
an acute viral infection like yellow fever virus, is not due to
HLA-C having been neglected in the scientific literature, but
rather reflects a true biological phenomenon. Notwithstanding,
future CD8+ T cell discovery efforts should include HLA-C,
in particular if one or more HLA-C restricted epitopes can be
suggested in a situation where there are no obvious HLA-A or
-B restricted candidates.
Concurrent with CD8+ T cell discovery, the “forward-reverse
immunology” approach also allowed HLA-II-restricted CD4+
T cell epitope discovery. The initial matrix-driven “forward”
analysis of 50 donors identified 192 CD4+ T cell stimulatory
YFV-derived 15mer peptides. This suggests that CD4+ T cell
epitopes are more numerous than CD8+ T cell epitopes,
perhaps as much as 2-3 times greater. If generalizable, this
would have important implications for CD4+ T cell immunity
since, everything else being equal, it would be more difficult
for a microorganism to escape many CD4+ T cell epitopes
than fewer CD8+ T cell epitopes. Addressing the number of
immunogenic open reading frames, other have also hinted at
a greater preponderance of CD4+ than CD8+ T cell epitopes
(59, 60); to the best of our knowledge, ours is the first
proteome-wide study that have made this observation at the
epitope level.
The identification of the restricting HLA class II element(s)
is a serious challenge in part due to different HLA-II allotypes
having overlapping peptide binding repertoires (61). In fact, this
problem is so manifest that Sette et al. have developed a panel
of 46 different single HLA-II transfected cell lines to identify
HLA-II restriction elements (62). It would be ideal if HLA-II
restrictions could be identified by predictors and then validated
by tetramer analysis. Unfortunately, the contemporary CD4+
T cell epitope discovery tools were immature (e.g., the early
NetMHCIIpan predictors were relatively inefficient and focused
solely on the HLA-DR isotypes), and access to peptide-MHC
class II tetramers was very limited. Moreover, ex vivo frequencies
of tetramer-positive CD4+ T cells tend to be <0.01%, which
make them difficult to detect. Thus, our CD4+ T cell epitope
discovery process was not exhaustive; however, as CD4+ T cell
discovery tools mature, we believe that the efficiency of CD4+ T
cell epitope discovery eventually should approach that of CD8+
T cell epitope discovery.
Here, using a panel of recombinant HLA-DR molecules,
we measured the binding affinity of the overlapping 15mer
peptides to the most common HLA-DR allotypes. For each
stimulatory 15mer peptide, this suggested which of the donor’s
HLA-DR molecules should be used to generate peptide-HLA-
DR tetramers for validation of CD4+ T cell epitopes. This “brute
force” approach was extended to 31 donors, where we tetramer-
validated 50 CD4+ T cell epitopes covering 13 different HLA-
DR allotypes (and one HLA-DP allotype). As of July 2019, the
IEDB has registered a total of 1,915 YFV-specific CD4+ T cell
epitopes as being “exact CD4+ T cell epitopes” (i.e., length 15
aa, or less) and restricted by an HLA-II defined at high (i.e.,
4-digit) resolution; 368 of which have been tetramer-validated.
Thus, the tetramer-validated YFV-specific CD4+ T cell epitopes
reported here represents a significant increase in the number of
tetramer-validated CD4+ T cell epitopes. It should be noted that
James and coworkers have identified and tetramer-validated 94
different YFV-specific CD4+ T cell epitopes [IEDB reference ID
1026930 (49)] that are 17 aa long and therefore fall just outside
the definition of an exact CD4+ T cell epitope.
A detailed examination of CD4+ T cell responses revealed a
phenomenon that could have profound biological and practical
implications for CD4+ T cell recognition. In many cases, two
consecutive overlapping 15mer peptides stimulated CD4+ T cell
responses, which were restricted by the sameHLA-DR restriction
element.When the responding CD4+ T cells were double-stained
with HLA-DR tetramers, which had been prepared with each
of the overlapping peptides of a 15mer pair and labeled with
a unique fluorochrome, we observed a plethora of different,
yet partially shared, CD4+ T cell specificities. Situations where
overlapping peptides are presented must occur regularly in vivo
since experiments sequencing natural peptides eluted of HLA-
II molecules frequently find large series of staggered peptides
surrounding each core region (63). Exploiting this wealth of
closely related peptides to engage a large number of different
CD4+ T cell specificities recognizing the same core region in
slightly different ways [something that actually was noted years
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ago (64)], may represent a biologically significant diversification
mechanism of CD4+ T cell responses reducing the risk of
pathogen escape and increasing the chances of recognizing a
given target. This phenomenon is also important for how CD4+
T cell responses should be analyzed. A single peptide-HLA-II
tetramer is likely to engage a range of T cells of various avidities
for the tetramer; something that might explain why single HLA-
II tetramers often appear to label a poorly defined, non-base
line separated, mono-specific CD4+ T cell population of low
frequency. If examined with two “overlapping” tetramer, this
could in reality turn out to be a heterogeneous collection of
better defined and separated CD4+ T cell populations of a higher
accumulated frequency. From a practical perspective, this implies
that double staining involving two overlapping peptide-HLA-II
tetramers will be needed to faithfully enumerate and monitor
any CD4+ T cell response. From a technical perspective, this will
increase the observed frequencies of specific CD4+ T cells for a
given specificity (i.e., increase the sensitivity of the analysis), and
it will increase the resolution of the flow cytometric analysis since
it may separate various positively staining subpopulations and
provide a better discrimination against negatively staining CD4+
T cells.
The T cell epitope discovery approach described here has
several advantages. In the forward immunology component,
an overlapping peptide library is used to search for peptides
containing CD4+ or CD8+ T cell epitopes. In the subsequent
reverse immunology component, pan-specific predictors are
used to identify the underlying epitope and its HLA restriction
element. These steps can be done in any (obviously outbred)
individual of any HLA haplotype using simple and standardized
conditions. This reduces the number and combinations of
peptides and HLA allotypes that should be considered for
peptide-HLA tetramer generation and used in the final validation
of the discovered T cell epitopes. As shown here, this approach
is efficient and, not surprisingly, it reduces the false discovery
rate. As peptide-HLA class I and II predictors and tetramer
technologies mature, this approach will eventually be able to
cover all frequently found HLA class I and II iso- and allotypes.
This approach is systematic, all-inclusive, complete, and global
in the sense that it includes all protein antigens and peptide
epitopes, encompasses both CD4+ and CD8+ T cell epitopes,
and can be extended to all individuals of all populations.
This approach could be extended to other attenuated live
virus vaccines (e.g., those targeting measles, mumps, rubella,
polio, and HPV). Compared to a strictly reverse approach,
significant disadvantages of the HFRI approach include the time
and cost associated with establishing a complete overlapping
peptide library as well as using a cellular readout as an initial
selection step. Therefore, this will probably not be justified if
the aim is to identify epitopes in an urgent effort involving
one donor (e.g., for cancer immunotherapy purposes); rather,
it would be appropriate if the aim is to examine a large
panel of donors in order to get population-wide data including
immunodominance, candidates for diagnostics and vaccine
development for infectious disease purposes (examples include
a range of emerging and re-emerging infectious diseases like
HIV, SARS, MERS, Chikungunya, Dengue, West Nile, Zika,
Ebola and SARS-CoV-2). For all of the above examples, the
proteomes are small enough that their entire proteomes could be
addressed by an overlapping peptide strategy using the number of
PBMC’s that could be obtained from a donor. Addressing larger
pathogen proteomes (e.g., herpes virus, bacteria or parasites;
or smaller highly variable virus like HIV and Dengue) in
their entirety would require either a selection process down-
sizing the source target protein antigens, or the development
of novel miniaturized, yet high-capacity, technologies. One
could envision that future investigations of emerging diseases
would include population-wide T cell epitope discovery efforts
using blood samples from patients, convalescents and/or long-
term survivors, which all possess important information on
T cell epitopes and responses. Similarly, one could envision
that approval and registration of new vaccines could include
population-wide analysis of T cell epitopes and responses. One
could also envision that population-wide information on T
cell epitopes and immunodominance could be used to design
subunit vaccines.
Another important advantage of the forward-reverse
approach presented here is the unbiased nature of the T
cell epitope discovery process. Whereas, current data-driven
bioinformatics peptide-MHC predictors are quite accurate, the
need for even better predictors stresses not only the need for
high-quality training data, but also the need for high-quality
validation data. In this context, there is an inherent problem
in most epitope discovery efforts being dependent on peptide-
MHC predictors since this effectively means that current T cell
epitope discovery submissions tend to be biased by current
predictors; something that might compromise the validation
and benchmarking of predictors. Having reasoned that our
forward-reverse approach captures about 90% of the true T cell
epitopes, we would like to propose that the resulting data is
largely unbiased and should serve as an appropriate benchmark
[others have reached similar conclusions (47)]. As an example,
we used the CD8+ T cell epitopes identified here to benchmark
current predictors. All current predictors were quite efficient
and accurate. The newer predictors, some of which included
immunopeptidomics and therefore may also reflect antigen
processing, were better than the older predictors [as also noted
by others (41)]. However, these improvements are incremental
and even the newest predictors were afflicted by high FDR’s.
Taken together, this could be interpreted as a need for a change
in how we predict T cell epitopes that is more fundamental than
merely acquiring more peptide-MHC affinity and/or stability
data e.g., by including T cell receptor specificities and repertoire
propensities. A source of unbiased T cell epitope data would be
instrumental in improving predicting tools.
In conclusion, for smaller proteomes, it is possible to design a
limited set of overlapping peptides spanning the entire proteome
and use these to reveal the vast majority, if not all, specific
CD4+ and CD8+ T cell responses concurrently; use predictors
to identify the underlying combination of peptide epitopes and
MHC restriction elements; and finally use this information to
construct suitable peptide-MHC multimers and validate the T
cell epitopes discovered. Performing this in cohorts of patients
or vaccinees allows for a systematic, global and cost-efficient
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analysis of CD4+ and CD8+ T cell epitopes, and evaluation of
their immunodominance.
MATERIALS AND METHODS
Study Approvals, Donors, and YFV
Vaccination
As previously described (26), this study was approved by the
Danish National Committee on Health Research Ethics (protocol
# H-1-2009-095), and the collection of data and cells was
approved by The Danish Data Protection Agency (permission
2008-41-2732). All volunteers gave written informed consent
prior to participation. Based on previous YFV vaccination history
and their International Card of Vaccination, healthy volunteers,
who for traveling purposes were about to receive a primary
YFV vaccination, were recruited. The attenuated YFV vaccine,
17D-204 (Sanofi Pasteur; marketed as Stamaril in more than 70
countries globally and as YF-VAX in the USA) was administered
intramuscularly. About 42% of the volunteers received an YFV
vaccination only, whereas the remaining 58% received additional
vaccines, typically killed, inactivated or subunit vaccines; in no
case was the YFV vaccine co-administered with another live
attenuated vaccine.
Blood Samples and PBMC Preparation
As previously described (26), blood samples were obtained just
prior to and after the YFV vaccination (typically day 10–20 post
vaccination, range 9–41 days). Peripheral blood mononuclear
cells (PBMC) were isolated by density gradient centrifugation
using Ficoll-PaqueTM Plus (GE Healthcare Europe, Brøndby,
Denmark). They were either examined directly ex vivo or
cryopreserved in 10% DMSO and 90% FCS at −150◦C for later
in vitro analysis.
High-Resolution HLA-Typing
Chromosomal DNA was prepared from the PBMC’s and
sequence-based typing (SBT) was used to perform high-
resolution (i.e., 4 digit) HLA-typing (Genome Diagnostics,
Utrecht, The Netherlands). All loci encoding classical HLA
molecules were typed i.e., the three class I Ioci, HLA-A, -B, -C
and the six class II loci, HLA-DRB1, -DRB3/4/5, -DQA1, -DQB1,
-DPA1, and -DPB1.
T Cell Marker Analysis
The PBMCs were analyzed ex vivo for the T cell markers, CD3,
CD4, and CD8, and the extracellular T cell activation markers,
CD38 and HLA-DR as previously described (26). Briefly, PBMCs
were incubated with fluorochrome-conjugated anti-CD3, -CD4,
-CD8, -CD38, and -HLA-DR antibodies for 30min at room
temperature, washed, fixed with 1% formaldehyde, and analyzed
by flow cytometry (LSR-II, BD Biosciences) using Diva software.
All antibodies were obtained from BioLegend (San Diego,
CA, USA).
Peptides
All peptides were synthesized by standard 9-
fluorenylmethyloxycarbonyl (FMOC) chemistry and purified by
reversed-phase high-performance liquid chromatography (purity
at least 80%, usually >95%), mass spectrometry validated and
lyophilized (Schafer-N, Copenhagen, Denmark). An overlapping
peptide library systematically covering the entire proteome of the
vaccine strain, YF-17D-204 (UniProt# P03314), was synthesized.
This encompassed the entire YF precursor protein of 3411 aa,
which could be represented by 850 peptides, each 15 aa long
and overlapping its neighboring peptides by 11 aa. In addition,
50 peptides, which were predicted to be binders to HLA-A or
-B supertype representatives by our NetMHCpan predictor,
were selected from putative products of alternative translation
initiation codons (65). One hundred and seven (107, or 11.9%)
of the total of 900 selected peptides were difficult to synthesize
and/or purify; many of which had long stretches of hydrophobic
aa. Adding one or two lysine to their N-or C-termini allowed
the successful synthesis and purification of 77 of these “difficult
to synthesize” peptides leaving 30 peptides that could not be
synthesized and/or purified. Thus, 870 (97%) of the selected
peptides could be included in this epitope screening effort.
These peptides were initially organized in a 30×30 matrix, and
eventually in four 15×15 matrices (Supplementary Figure S1).
Ex-vivo ELISpot Assay
Fresh or thawed PBMCs were tested using an Interferon-γ
(IFNγ) specific ELI Spot assay as previously described (66).
Briefly, 2–3 × 105 cells/well were plated in an ELI Spot plate
(MAHAS4510, Merck Millipore, USA) and in vitro cultured
for 18–24 h in media supplemented with or without peptide
at 0.5µM [or, as positive control, with 1µg/ml Staphylococcal
enterotoxin B (SEB, Sigma Aldrich, St. Louis, USA)]. An AP
conjugate substrate kit (Bio-Rad) was used for visualization
of spots. ELI spots were counted using a CTL ImmunoSpot
series 5 UV Analyzer. ImmunoSpot 5.0.9 software (C.T.L.,
Shaker Heights, USA) was used for analysis. Wells with spot-
forming units SPU > 2 times the background wells were
considered positive.
Cell Culture and in vitro Peptide
Stimulation
PBMCs were incubated overnight (37◦C, 5% CO2) in X-vivo
15 media (Fisher Scientific) supplemented with 5% AB Serum
(Invitrogen) and amixture of relevant peptides at a concentration
of 0.5µM of each peptide. The cells were harvested and washed,
and subsequently plated in 24-well plates at a concentration of 5
× 106/ml supplemented with 50 U/ml IL-2 for expansion. Fresh
media and IL-2 were supplemented every second day until the
cells were harvested at day 8, and IL-15 (15 ng/ml) was added the
last 4 days.
In vitro Intracellular Cytokine Staining (ICS)
Assay
In vitro cultured PBMC’s were harvested, washed, and aliquoted
at 2–4 × 105 cells/well in a round bottom 96 well-plate. The
in vitro cultured PBMC’s were stimulated for 4 h at 37◦C, 5%
CO2 with, for the matrix analysis, each of the 15 column and
15 row mixes (1 µM/peptide), and for the epitope identification
with a single peptide (0.8µM). After 1 h of stimulation 1µg/mL
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Brefeldin A (BD Biosciences) was added. The cells were
subsequently permeabilized (Becton Dickinson Permeabilizing
solution 2) and stained with anti-CD3-Pacific Blue, anti-CD4-
PerCp, anti-CD8-APC, anti-CD69-PE, and anti-IFNγ-FITC,
according to the “FastImmune” protocol (Becton Dickinson).
The cells were subsequently analyzed by flow cytometry using
a LSRII (BD Biosciences). The gating strategy is illustrated in
Supplementary Figure S4. Staining of more than 0.8% of CD8+
or CD4+ T cells was considered positive.
Peptide-HLA-I Tetramers
HLA class I tetramers were produced as previously described
(67). Briefly, recombinant, biotinylated HLA class I heavy chain,
human β2-microglobulin and peptide were incubated in 50mM
tris-maleate pH 6.8 and 0.1% Pluronic F68 for 48 h at 18◦C.
The resulting monomers were tetramerized by addition of
fluorochrome labeled Streptavidin (Streptavidin-phycoerythrin
(SA-PE), Streptavidin-allophycocyanin (SA-APC), Streptavidin-
Brilliant Violet 421 (SA-BV421), and/or Streptavidin-Brilliant
Violet 605 (SA-BV605); all from BioLegend) sequentially over
60min at a 1:4 molar ratio of streptavidin to monomer. For
T cell analysis, pellets of 106 PBMCs obtained ex vivo, or
pellets from 2 × 105 cells obtained from in vitro peptide
stimulated cell cultures, were re-suspended in a 10 µl tetramer
solution at a final concentration of ca. 30 nM, and incubated
for 20min at room temperature, followed by 30min incubation
with fluorochrome conjugated anti-CD3, -CD8, -CD38, and -
HLA-DR antibodies. The cells were analyzed by flowcytometry
(Fortessa or LSR-II, BD Biosciences) using Diva software.
Supplementary Figure S5, a NS5286−295-A∗01:01 tetramer ex
vivo staining pre- and post-YF vaccination, illustrates the
tetramer staining and background level.
Peptide-HLA-II Tetramers
HLA-DRA and HLA-DRB chains were produced as previously
described (42). For tetramer production, HLA-DRA and HLA-
DRB chains were mixed in a 1:1.5 ratio and incubated in
3µM peptides in PBS (pH 7.4) with 20% glycerol and 0.1%
Pluronic F68 for 96 h at 18◦C. The resulting monomers were
buffer changed into PBS with 5% glycerol and concentrated
on 10kD Vivaspin (Satorius) and quantitated by Luminescent
Oxygen Channeling Immunoassay (LOCI)-driven assay (42).
The resulting monomers were tetramerized by addition of
fluorochrome labeled Streptavidin (Streptavidin-phycoerythrin
(SA-PE) or Streptavidin-allophycocyanin (SA-APC); both from
BioLegend) sequentially over 60min at a 1:4 molar ratio of
streptavidin to monomer. For T cell analysis, pellets of 4 ×
105 cells obtained from in vitro peptide stimulated cell cultures,
were re-suspended in a 40 µl tetramer diluted in media to
a final concentration of ca. 30 nM, and incubated for 1 h
at 37◦C, followed by 30min incubation with fluorochrome
conjugated anti-CD3, -CD8, -CD38, and -HLA-DR antibodies.
The cells were analyzed by flowcytometry (Fortessa or LSR-II, BD
Biosciences) using Diva software.
Predictions of CD8+ T Cell Epitopes and
HLA-I Restriction
For each donor, all 15mer peptides eliciting a CD8+ T
cell response were submitted to our bioinformatics predictor,
NetMHCpan (36), which returned a prioritized list of predicted
optimal epitopes, which could bind to any of the up to six HLA-A,
-B, or-C molecules of the donor in question.
Predictions of CD4+ T Cell Epitopes and
HLA-II Restriction
For each donor, all 15mer peptides eliciting a CD4+ T
cell response were submitted to our bioinformatics predictor,
NetMHCIIpan (68), which returned a prioritized list of predicted
epitopes including a predicted core-region, which could bind to
any of the up to four HLA-DRB1, or-DRB3/4/5 molecules of the
donor in question.
Peptide-HLA Class I Stability
Measurements
The stability of peptide-HLA class I complexes was measured
using dissociation of 125I radiolabelled β2m in a scintillation
proximity assay (SPA) as previously described (69). Briefly,
recombinant, biotinylated HLA class I heavy chains were diluted
into a refolding buffer containing the test peptide and trace
amounts of 125I radiolabeled β2m, and allowed to refold at
18◦C for 24 h in a Streptavidin-coated scintillation microplate
(Flashplate PLUS, Perkin Elmer, Boston, MA). Dissociation
was initiated by adding excess unlabeled β2m and placing the
microplate in a scintillation counter (TopCount NXT, Packard)
adjusted to 37◦C. Reading the microplate continuously for 24 h
allowed determination of the dissociation of radiolabeled β2m.
Biochemical Peptide HLA Class II Binding
Assays
Peptide-HLA-II binding affinities were determined using
a previously described Luminescent Oxygen Channeling
Immunoassay (LOCI)-driven assay (42). Briefly, denatured and
purified recombinant HLA-II alpha and beta chains were diluted
into a refolding buffer (tris-maleate buffer, pH 6.6) with graded
concentrations of the test peptide, and incubated for 48 h at 18◦C
to allow for equilibrium to be reached. The peptide concentration
leading to half-saturation (ED50) was determined as previously
described (42). Under the limited receptor concentrations used
here, the ED50 reflects the affinity of the interaction.
Statistics
GraphPad Prism 8 was used for statistical analyses (unpaired
and paired Mann-Whitney-Wilcoxon tests, unpaired and paired
t-tests, Fishers exact test, and ROC analysis).
DATA AVAILABILITY STATEMENT
All datasets presented in this study are included in the
article/Supplementary Material.
Frontiers in Immunology | www.frontiersin.org 22 August 2020 | Volume 11 | Article 1836
Stryhn et al. Comprehensive T Cell Epitope Discovery
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by Danish National Committee on Health Research
Ethics (protocol # H-1-2009-095). The patients/participants
provided their written informed consent to participate in
this study.
AUTHOR CONTRIBUTIONS
AS, JC, MN, AR, and SB contributed to the conception and
design of the study. SB, AS, ST, MG, and MHan recruited
donors, vaccinated, and collected blood samples before and
after vaccination. MK, MR, and MHar performed biochemical
analysis. AS, MN, and SB performed the statistical analysis.
AS wrote the first draft of the manuscript. AS and SB wrote
the manuscript with sections contributed by MN and AR. All
authors contributed to manuscript revision, read and approved
the submitted version.
FUNDING
This project has been funded in part with Federal funds from
theNational Institute of Allergy and Infectious Diseases, National
Institutes of Health, Department of Health and Human Services,
under, Contract No. HHSN272200900045C.
ACKNOWLEDGMENTS
The authors thank doctors and nurses at the two recruiting
centers and the Blood Bank of the University Hospital, and
members of the Buus laboratory for expert technical assistance.
SUPPLEMENTARY MATERIAL




1. Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of
MHC class I andMHC class II antigen presentation.Nat Rev Immunol. (2011)
11:823–36. doi: 10.1038/nri3084
2. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility
complex class I-restricted T lymphocyte responses. Annu Rev Immunol.
(1999) 17:51–88. doi: 10.1146/annurev.immunol.17.1.51
3. Buus S. Description and prediction of peptide-MHC binding:
the human MHC project. Curr Opin Immunol. (1999) 11:209–
13. doi: 10.1016/S0952-7915(99)80035-1
4. Lauemoller SL, Kesmir C, Corbet SL, Fomsgaard A, Holm A, Claesson MH,
et al. Identifying cytotoxic T cell epitopes from genomic and proteomic
information: The human MHC project. Rev Immunogenet. (2000) 2:477–91.
5. Martini S, Nielsen M, Peters B, Sette A. The immune epitope database
and analysis resource program 2003-2018: reflections and outlook.
Immunogenetics. (2020) 72:57–76. doi: 10.1007/s00251-019-01137-6
6. Caron E, Aebersold R, Banaei-Esfahani A, Chong C, Bassani-Sternberg M. A
case for a human immuno-peptidome project consortium. Immunity. (2017)
47:203–8. doi: 10.1016/j.immuni.2017.07.010
7. Alvarez B, Barra C, Nielsen M, Andreatta M. Computational tools for the
identification and interpretation of sequence motifs in immunopeptidomes.
Proteomics. (2018) 18:e1700252. doi: 10.1002/pmic.201700252
8. Editorial: The problem with neoantigen prediction. Nat Biotechnol. (2017)
35:97. doi: 10.1038/nbt.3800
9. Kessler JH, Melief CJ. Identification of T-cell epitopes for cancer
immunotherapy. Leukemia. (2007) 21:1859–74. doi: 10.1038/sj.leu.2404787
10. Muller M, Gfeller D, Coukos G M. Bassani-sternberg: ‘hotspots’ of antigen
presentation revealed by human leukocyte antigen ligandomics for neoantigen
prioritization. Front Immunol. (2017) 8:1367. doi: 10.3389/fimmu.2017.
01367
11. Richters MM, Xia H, Campbell KM, Gillanders WE, Griffith OL, Griffith M.
Best practices for bioinformatic characterization of neoantigens for clinical
utility. Genome Med. (2019) 11:56. doi: 10.1186/s13073-019-0666-2
12. Andreatta M, Trolle T, Yan Z, Greenbaum JA, Peters B, Nielsen
M. An automated benchmarking platform for MHC class II
binding prediction methods. Bioinformatics. (2018) 34:1522–
8. doi: 10.1093/bioinformatics/btx820
13. Racle J, Michaux J, Rockinger GA, Arnaud M, Bobisse S, Chong C,
et al. Robust prediction of HLA class II epitopes by deep motif
deconvolution of immunopeptidomes. Nat Biotechnol. (2019) 37:1283–
6. doi: 10.1038/s41587-019-0289-6
14. Alvarez B, Reynisson B, Barra C, Buus S, Ternette N, Connelley T, et al.
NNAlign_MA; MHC peptidome deconvolution for accurate MHC binding
motif characterization and improved T-cell epitope predictions. Mol Cell
Proteomics. (2019) 18:2459–77. doi: 10.1074/mcp.TIR119.001658
15. Barra C, Alvarez B, Paul S, Sette A, Peters B, Andreatta M, et al. Footprints
of antigen processing boost MHC class II natural ligand predictions. Genome
Med. (2018) 10:84. doi: 10.1186/s13073-018-0594-6
16. Nielsen M, Andreatta M. NetMHCpan-3.0; improved prediction of
binding to MHC class I molecules integrating information from
multiple receptor and peptide length datasets. Genome Med. (2016)
8:33. doi: 10.1186/s13073-016-0288-x
17. Assarsson E, Sidney J, Oseroff C, Pasquetto V, Bui HH, Frahm N, et al.
A quantitative analysis of the variables affecting the repertoire of T cell
specificities recognized after vaccinia virus infection. J Immunol. (2007)
178:7890–901. doi: 10.4049/jimmunol.178.12.7890
18. Lutgendorf MA, Stoll KA. Why 99% may not be as good as you think it is:
limitations of screening for rare diseases. J Matern Fetal Neonatal Med. (2016)
29:1187–9. doi: 10.3109/14767058.2015.1039977
19. YadavM, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al.
Predicting immunogenic tumour mutations by combining mass spectrometry
and exome sequencing. Nature. (2014) 515:572–6. doi: 10.1038/nature14001
20. Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Lower M, et al.
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic
immunity against cancer.Nature. (2017) 547:222–6. doi: 10.1038/nature23003
21. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic
personal neoantigen vaccine for patients with melanoma. Nature. (2017)
547:217–21. doi: 10.1038/nature22991
22. Monath TP, Gershman M, Staples JE, Barrett ADT. Yellow fever vaccine.
In: Plotkin SAW, Orenstein PA. Vaccines. Offit Elsevier/Saunders (2012).
doi: 10.1016/B978-1-4557-0090-5.00043-4
23. Monath TP, Vasconcelos PF. Yellow fever. J Clin Virol. (2015) 64:160–
73. doi: 10.1016/j.jcv.2014.08.030
24. Garske T, Van Kerkhove MD, Yactayo S, Ronveaux O, Lewis RF, Staples JE,
et al. Yellow fever expert: yellow fever in africa: estimating the burden of
disease and impact of mass vaccination from outbreak and serological data.
PLoS Med. (2014) 11:e1001638. doi: 10.1371/journal.pmed.1001638
25. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S,
Masopust D, et al. Human effector and memory CD8+ T cell
responses to smallpox and yellow fever vaccines. Immunity. (2008)
28:710–22. doi: 10.1016/j.immuni.2008.02.020
26. Kongsgaard M, Bassi MR, Rasmussen M, Skjodt K, Thybo S, Gabriel M,
et al. Adaptive immune responses to booster vaccination against yellow fever
Frontiers in Immunology | www.frontiersin.org 23 August 2020 | Volume 11 | Article 1836
Stryhn et al. Comprehensive T Cell Epitope Discovery
virus are much reduced compared to those after primary vaccination. Sci Rep.
(2017) 7:662. doi: 10.1038/s41598-017-00798-1
27. Barban V, Girerd Y, AguirreM, Gulia S, Petiard F, Riou P, et al. High stability of
yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale
production. Vaccine. (2007) 25:2941–50. doi: 10.1016/j.vaccine.2006.06.082
28. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E,
Van den Eynde B, et al. A gene encoding an antigen recognized by
cytolytic T lymphocytes on a human melanoma. Science. (1991) 254:1643–
7. doi: 10.1126/science.1840703
29. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel
A, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on
HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J
Exp Med. (1992) 176:1453–7. doi: 10.1084/jem.176.5.1453
30. Maecker B, von B-B, Anderson KS, Vonderheide RH, Schultze
JL. Linking genomics to immunotherapy by reverse immunology–
’immunomics’ in the new millennium. Curr Mol Med. (2001)
1:609–19. doi: 10.2174/1566524013363447
31. Hombrink P, Hassan C, Kester MG, de Ru AH, van Bergen CA, Nijveen
H, et al. Discovery of T cell epitopes implementing HLA-peptidomics
into a reverse immunology approach. J Immunol. (2013) 190:3869–
77. doi: 10.4049/jimmunol.1202351
32. Dupuy A, Despres P, Cahour A, Girard M, Bouloy M. Nucleotide sequence
comparison of the genome of two 17D-204 yellow fever vaccines. Nucleic
Acids Res. (1989) 17:3989. doi: 10.1093/nar/17.10.3989
33. Lucas A, Lucas M, Stryhn A, Keane NM, McKinnon E, Pavlos R, et al.
Abacavir-reactive memory T cells are present in drug naive individuals. PLoS
ONE. (2015) 10:e0117160. doi: 10.1371/journal.pone.0117160
34. Lund O, Nascimento EJ, Maciel M Jr, Nielsen M, LarsenMV, Lundegaard C Jr,
et al. Human leukocyte antigen (HLA) class I restricted epitope discovery in
yellow fewer and dengue viruses: importance of HLA binding strength. PLoS
ONE. (2011) 6:e26494. doi: 10.1371/journal.pone.0026494
35. Bovay A, Zoete V, Dolton G, Bulek AM, Cole DK, Rizkallah PJ,
et al. Fuertes marraco: T cell receptor alpha variable 12-2 bias in the
immunodominant response to yellow fever virus. Eur J Immunol. (2018)
48:258–72. doi: 10.1002/eji.201747082
36. Nielsen M, Lundegaard C, Blicher T, Lamberth K, Harndahl M, Justesen S,
et al. NetMHCpan, a method for quantitative predictions of peptide binding
to any HLA-A and -B locus protein of known sequence. PLoS ONE. (2007)
2:e796. doi: 10.1371/journal.pone.0000796
37. Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-
4.0: improved peptide-mhc class i interaction predictions integrating eluted
ligand and peptide binding affinity data. J Immunol. (2017) 199:3360–
8. doi: 10.4049/jimmunol.1700893
38. O’Donnell TJ, Rubinsteyn A, Bonsack M, Riemer AB, Laserson U,
Hammerbacher J. MHCflurry: open-source class I MHC binding affinity
prediction. Cell Syst. (2018) 7:129–32.e4. doi: 10.1016/j.cels.2018.05.014
39. Bassani-Sternberg M, Chong C, Guillaume P, Solleder M, Pak H, Gannon
PO, et al. Deciphering HLA-I motifs across HLA peptidomes improves neo-
antigen predictions and identifies allostery regulating HLA specificity. PLoS
Comput Biol. (2017) 13:e1005725. doi: 10.1371/journal.pcbi.1005725
40. Rasmussen M, Fenoy E, Harndahl M, Kristensen AB, Nielsen IK, Nielsen
M, et al. Pan-Specific prediction of peptide-MHC class I complex stability,
a correlate of T cell immunogenicity. J Immunol. (2016) 197:1517–
24. doi: 10.4049/jimmunol.1600582
41. Mei S, Li F, Leier A, Marquez-Lago TT, Giam K, Croft NP, et al. A
comprehensive review and performance evaluation of bioinformatics tools
for HLA class I peptide-binding prediction. Brief Bioinform. (2019). 21:1119–
35. doi: 10.1093/bib/bbz051
42. Justesen S, Harndahl M, Lamberth K, Nielsen LL, Buus S. Functional
recombinant MHC class II molecules and high-throughput peptide-binding
assays. Immunome Res. (2009) 5:2. doi: 10.1186/1745-7580-5-2
43. Zilberberg J, Feinman R, Korngold R. Strategies for the identification
of T cell-recognized tumor antigens in hematological malignancies
for improved graft-versus-tumor responses after allogeneic blood
and marrow transplantation. Biol Blood Marrow Transplant. (2015)
21:1000–7. doi: 10.1016/j.bbmt.2014.11.001
44. Boon T, van der Bruggen P. Human tumor antigens recognized by T
lymphocytes. J Exp Med. (1996) 183:725–9. doi: 10.1084/jem.183.3.725
45. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A.
Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. (1994)
12:337–65. doi: 10.1146/annurev.iy.12.040194.002005
46. Jing L, Chong TM,McClurkan CL, Huang J, Story BT, Koelle DM. Diversity in
the acute CD8T cell response to vaccinia virus in humans. J Immunol. (2005)
175:7550–9. doi: 10.4049/jimmunol.175.11.7550
47. Sakabe S, Sullivan BM, Hartnett JN, Robles-Sikisaka R, Gangavarapu K,
Cubitt B, et al. Analysis of CD8(+) T cell response during the 2013-2016
Ebola epidemic in West Africa. Proc Natl Acad Sci USA. (2018) 115:E7578–
86. doi: 10.1073/pnas.1806200115
48. Jing L, Laing KJ, Dong L, Russell RM, Barlow RS, Haas JG, et al. Extensive
CD4 and CD8T cell cross-reactivity between alphaherpesviruses. J Immunol.
(2016) 196:2205–18. doi: 10.4049/jimmunol.1502366
49. James EA, LaFond RE, Gates TJ, Mai DT, Malhotra U, Kwok WW. Yellow
fever vaccination elicits broad functional CD4+ T cell responses that
recognize structural and nonstructural proteins. J Virol. (2013) 87:12794–
804. doi: 10.1128/JVI.01160-13
50. Axelsson-Robertson R, Loxton AG, Walzl G, Ehlers MM, Kock MM,
Zumla A, et al. A broad profile of co-dominant epitopes shapes the
peripheral mycobacterium tuberculosis specific CD8+ T-cell immune
response in South African patients with active tuberculosis. PLoS ONE. (2013)
8:e58309. doi: 10.1371/journal.pone.0058309
51. Chen W, McCluskey J. Immunodominance and immunodomination: critical
factors in developing effective CD8+T-cell-based cancer vaccines.Adv Cancer
Res. (2006) 95:203–47. doi: 10.1016/S0065-230X(06)95006-4
52. Kloverpris HN, McGregor R, McLaren JE, Ladell K, Harndahl M, Stryhn A,
et al. CD8+ TCR Bias and immunodominance in HIV-1 Infection. J Immunol.
(2015) 194:5329–45. doi: 10.4049/jimmunol.1400854
53. Bashirova AA, Martin MP, McVicar DW, Carrington M. The
killer immunoglobulin-like receptor gene cluster: tuning the
genome for defense. Annu Rev Genomics Hum Genet. (2006)
7:277–300. doi: 10.1146/annurev.genom.7.080505.115726
54. Snary D, Barnstable CJ, Bodmer WF, Crumpton MJ. Molecular structure of
human histocompatibility antigens: the HLA-C series. Eur J Immunol. (1977)
7:580–5. doi: 10.1002/eji.1830070816
55. Zemmour J, Parham P. Distinctive polymorphism at the HLA-C locus:
implications for the expression of HLA-C. J Exp Med. (1992) 176:937–
50. doi: 10.1084/jem.176.4.937
56. Apps R, Meng Z, Del Prete GQ, Lifson JD, Zhou M, Carrington M.
Relative expression levels of the HLA class-I proteins in normal and HIV-
infected cells. J Immunol. (2015) 194:3594–600. doi: 10.4049/jimmunol.
1403234
57. Petersdorf EW, Gooley TA, Malkki M, Bacigalupo AP, Cesbron A,
Du Toit E, et al. International histocompatibility working group
in hematopoietic cell: HLA-C expression levels define permissible
mismatches in hematopoietic cell transplantation. Blood. (2014)
124:3996–4003. doi: 10.1182/blood-2014-09-599969
58. Apps R, Qi Y, Carlson JM, Chen H, Gao X, Thomas R, et al. Influence
of HLA-C expression level on HIV control. Science. (2013) 340:87–
91. doi: 10.1126/science.1232685
59. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, et al.
Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells
dominate the memory compartments of exposed subjects. J Exp Med. (2005)
202:673–85. doi: 10.1084/jem.20050882
60. Jing L, Schiffer JT, Chong TM, Bruckner JJ, Davies DH, Felgner PL, et al.
CD4 T-cell memory responses to viral infections of humans show pronounced
immunodominance independent of duration or viral persistence. J Virol.
(2013) 87:2617–27. doi: 10.1128/JVI.03047-12
61. Greenbaum J, Sidney J, Chung J, Brander C, Peters B, Sette A.
Functional classification of class II human leukocyte antigen (HLA)
molecules reveals seven different supertypes and a surprising degree
of repertoire sharing across supertypes. Immunogenetics. (2011) 63:325–
35. doi: 10.1007/s00251-011-0513-0
62. McKinney DM, Southwood S, Hinz D, Oseroff C, Arlehamn CS,
Schulten V, et al. A strategy to determine HLA class II restriction
broadly covering the DR, DP, and DQ allelic variants most commonly
expressed in the general population. Immunogenetics. (2013)
65:357–70. doi: 10.1007/s00251-013-0684-y
Frontiers in Immunology | www.frontiersin.org 24 August 2020 | Volume 11 | Article 1836
Stryhn et al. Comprehensive T Cell Epitope Discovery
63. Bergseng E, Dørum S, Arntzen MØ, Nielsen M, Nygård S,
Buus S. Different binding motifs of the celiac disease-associated
HLA molecules DQ2.5, DQ2.2, and DQ7.5 revealed by relative
quantitative proteomics of endogenous peptide repertoires.
Immunogenetics. (2015) 67:73–84. doi: 10.1007/s00251-014-
0819-9
64. Sette A, Buus S, Colon S, Smith JA, Miles C, Grey HM. Structural
characteristics of an antigen required for its interaction with Ia
and recognition by T cells. Nature. (1987) 328:395–9. doi: 10.1038/
328395a0
65. Shastri N, Nguyen V, Gonzalez F. Major histocompatibility class I molecules
can present cryptic translation products to T-cells. J Biol Chem. (1995)
270:1088–91. doi: 10.1074/jbc.270.3.1088
66. Wang M, Lamberth K, Harndahl M, Roder G, Stryhn A, Larsen
MV, et al. CTL epitopes for influenza A including the H5N1 bird
flu; genome-, pathogen-, HLA-wide screening. Vaccine. (2007) 25:2823–
31. doi: 10.1016/j.vaccine.2006.12.038
67. Leisner C, Loeth N, Lamberth K, Justesen S, Sylvester-Hvid C, Schmidt EG,
et al. One-pot, mix-and-read peptide-MHC tetramers. PLoS ONE. (2008)
3:e1678. doi: 10.1371/journal.pone.0001678
68. Nielsen M, Lundegaard C, Blicher T, Peters B, Sette A, Justesen S,
et al. Quantitative predictions of peptide binding to any HLA-DR
molecule of known sequence: NetMHCIIpan. PLoS Comput Biol. (2008)
4:e1000107. doi: 10.1371/journal.pcbi.1000107
69. Harndahl M, Rasmussen M, Roder G, Buus S. Real-time, high-throughput
measurements of peptide-MHC-I dissociation using a scintillation proximity
assay. J Immunol Methods. (2011) 374:5–12. doi: 10.1016/j.jim.2010.10.012
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Stryhn, Kongsgaard, Rasmussen, Harndahl, Østerbye, Bassi,
Thybo, Gabriel, Hansen, Nielsen, Christensen, Randrup Thomsen and Buus. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Immunology | www.frontiersin.org 25 August 2020 | Volume 11 | Article 1836
Supplementary discussion of the possible bias introduced by the use of an ICS assay to screen 
for T cell responses. 
Prior to the ICS assay, the T cells were expanded by in vitro culture with a pool of peptides for 8 
days in a media supplemented with IL-2 and IL-15. This could potentially introduce a bias in the 
epitope discovery process since any T cell reactivity that was not maintained under these conditions 
could have be missed. A priori, we believe that the epitopes discovered here represents the ex vivo 
anti-virus response since it has been demonstrated, at least for CD8+ T cells, that acute and transient 
viral infections generate a stable TcR repertoire (Welsh, PubMed Identifier 9841914). This suggests 
that the specificities of YFV-specific acute and memory T cell responses are identical. Furthermore, 
had important responses been missed, one would expect that a strictly reverse immunology 
approach as the one shown in Supplementary Table III would have identified epitopes missed by 
the HFRI approach. However, when we compared the two approaches and ex vivo tested 34 
tetramers based on predicted, but not HFRI, identified peptides, we only identified one of these as 
an epitope missed by the HFRI approach. Thus, we conclude that we have not systematically 
missed major epitopes.   
Supplementary results and discussion of the performance of the hybrid forward-reverse 
immunology (HFRI) vs reverse immunology approaches. 
Additional opportunities arose for comparing the HFRI and reverse immunology approaches. For 
donor YF1067, the 27 stimulatory 15mer peptides were submitted to the contemporary NetMHCpan 
2.4, which returned 156 submer-HLA-I predictions per stimulatory peptide. For each stimulatory 
peptide, we retrospectively asked how each of the 19 validated epitopes of donor YF1067 ranked 
amongst the 156 submers predictions. In 23(≈85%) of the 27 submissions, the number one ranking 
prediction ended up being validated as an epitope (Table I). If one applied the contemporary 
NetMHCpan 2.4 predictor at a stringent %Rank cut-off of 0.5%, it would have correctly identified 
17 (89%) of the 19 epitopes (true positives); missed 2 (false negatives), and erroneously included 
14 (false positives) leading to a false positive rate of 14/(14+19) = 42%. The current version, 
NetMHCpan4.0, could have been applied at an even more stringent %Rank cut-off of 0.25%, which 
would have correctly identified 18 (95%) of the 19 epitopes (true positives); 1 would have been 
missed (false negative), and 6 would have been erroneously included (false positives) leading to a 
false positive rate of 6/(6+19) = 24%. 
Had the predictors been applied, not to the 27 stimulatory peptides, but to the entire YFV proteome, 
with the above cut-offs and the HLA-A and -B allotypes of YF1067, the number of false positive 
predictions included by NetMHCpan 2.4 would have been 187, whereas the current NetMHCpan4.0 
would have included 158 false positive predictions. 
This supports the general conclusion that the present HFRI approach ranks epitope at the very top 
of the list of candidates while decimating the false discovery rate. It also demonstrates that the 
current predictors have improved compared to older versions maintaining a high sensitivity while 
reducing the false positive rate. Nonetheless, there is still room for further improvements. 
 
C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13 C14 C15 C16 C17 C18 C19 C20 C21 C22 C23 C24 C25 C26 C27 C28 C29 C30
R1 25220 25221 25222 25223 25224 25225 25226 25227 25228 25229 25230 25231 25232 25233 25234 25235 25236 25237 25238 25239 25240 25241 25242 25243 25244 25245 25248
R2 25249 25250 25251 25252 25253 25254 25255 25256 25257 25258 25259 25260 25261 25262 25263 25264 25265 25266 25267 25268 25269 25270 25271 25272 25273 25274 25275 25276 25277 27463
R3 25278 25279 25280 25281 25282 25283 25285 25286 25288 25289 25290 25291 25292 25293 25295 25296 25297 25298 25299 25300 25301 25302 25303 25304 25305 25306 25307 25308 25309 27464
R4 25310 25311 25312 25313 25314 25315 25316 25317 25318 25319 25320 25321 25322 25323 25324 25325 25326 25327 25328 25329 25330 25331 25332 25333 25334 25335 25336 25337 25338 27465
R5 25339 25340 25341 25342 25343 25344 25345 25346 25347 25348 25349 25350 25351 25352 25353 25354 25355 25356 25357 25358 25359 25360 25361 25362 25363 25364 25365 25366 27466
R6 25367 25368 25369 25370 25371 25372 25373 25374 25375 25376 25377 25378 25379 25380 25381 25382 25383 25384 25385 25386 25387 25388 25389 25390 25391 25392 25393 25394 25395
R7 25396 25397 25398 25399 25400 25401 25402 25406 25407 25412 25413 25414 25415 25416 25417 25418 25419 25420 25421 25422 25423 25425 25426 25427 25428 25429 25430 25431 25432
R8 25433 25434 25435 25436 25437 25438 25439 25440 25441 25442 25443 25444 25445 25446 25447 25448 25449 25450 25451 25452 25453 25456 25457 25458 25459 25460 25461 25462 25463 27468
R9 25464 25465 25466 25467 25468 25469 25470 25471 25472 25473 25474 25475 25476 25477 25478 25479 25480 25481 25482 25483 25484 25485 25486 25487 25488 25489 25490 25491
R10 25492 25493 25494 25495 25496 25497 25498 25499 25500 25501 25502 25503 25505 25506 25507 25508 25509 25512 25513 25514 25515 25516 25517 25518 25519 25520 25521 25522 25523
R11 25524 25525 25526 25527 25528 25529 25530 25531 25532 25533 25534 25536 25537 25538 25539 25540 25541 25542 25545 25546 25547 25548 25549 25550 25551 25552 25553 25554
R12 25555 25556 25557 25558 25559 25560 25562 25563 25564 25565 25566 25568 25569 25570 25571 25572 25573 25574 25575 25576 25577 25578 25579 25580 25581 25582 25583 25584 25585 27475
R13 25586 25587 25588 25589 25590 25591 25592 25593 25594 25595 25596 25597 25598 25599 25600 25601 25602 25603 25604 25605 25606 25607 25608 25609 25610 25611 25612 25613 27473
R14 25614 25615 25616 25617 25618 25619 25620 25621 25622 25623 25624 25625 25626 25627 25628 25629 25630 25631 25632 25633 25634 25635 25636 25637 25638 25639 25640 25641 25642
R15 25643 25644 25645 25646 25647 25648 25649 25650 25651 25652 25653 25654 25655 25656 25657 25658 25659 25660 25661 25662 25663 25664 25665 25666 25667 25668 25669 25670 25671
R16 25672 25673 25674 25675 25676 25677 25678 25679 25680 25681 25682 25683 25684 25685 25686 25687 25688 25689 25690 25691 25692 25693 25694 25695 25696 25697 25698 25699 25700
R17 25701 25702 25703 25704 25705 25706 25707 25708 25709 25710 25711 25712 25713 25714 25715 25716 25717 25718 25719 25720 25721 25722 25723 25724 25725 25726 25727 25728 25729
R18 25730 25731 25732 25733 25734 25735 25736 25737 25738 25739 25740 25741 25742 25743 25744 25745 25746 25747 25748 25749 25750 25751 25752 25753 25754 25755 25756 25757
R19 25762 25763 25764 25765 25766 25767 25768 25769 25770 25771 25772 25775 25776 25777 25778 25779 25782 25783 25784 25785 25786 25787 25788 25789 25790 25791
R20 25792 25793 25794 25795 25796 25797 25798 25799 25801 25802 25803 25804 25805 25806 25808 25810 25811 25812 25813 25814 25815 25816 25817 25818 25819 25820 25821 25822 27476
R21 25823 25824 25825 25829 25830 25831 25832 25833 25834 25835 25837 25838 25839 25840 25841 25842 25843 25844 25845 25846 25847 25848 25849 25850 25851 25852 25853 25854 27477
R22 25855 25856 25857 25858 25859 25860 25861 25862 25863 25864 25865 25866 25867 25868 25869 25870 25871 25872 25873 25874 25875 25876 25877 25878 25879 25880 25881 25882 25883
R23 25885 25886 25887 25888 25889 25890 25891 25892 25893 25894 25895 25896 25897 25898 25899 25900 25901 25902 25903 25904 25905 25906 25907 25908 25909 25910 25911 25912 25913 27479
R24 25914 25915 25916 25917 25918 25919 25920 25921 25922 25923 25924 25925 25926 25927 25928 25929 25930 25931 25932 25933 25934 25935 25936 25937 25938 25939 25940 25941 25942 27480
R25 25943 25944 25945 25946 25947 25948 25949 25950 25951 25952 25953 25954 25955 25956 25957 25958 25959 25960 25961 25962 25963 25964 25965 25966 25967 25968 25969 25970 25971
R26 25972 25973 25974 25975 25976 25977 25978 25979 25980 25981 25982 25983 25984 25985 25986 25987 25988 25989 25990 25991 25992 25993 25994 25995 25996 25997 25998 25999 26000 27471
R27 26001 26002 26003 26004 26005 26006 26007 26008 26009 26010 26011 26012 26013 26014 26015 26016 26017 26018 26019 26020 26021 26022 26023 26024 26025 26026 26027 26028 26029
R28 26030 26031 26032 26033 26035 26036 26037 26038 26039 26040 26041 26042 26043 26044 26045 26046 26047 26048 26049 26050 26051 26052 26053 26054 26055 26056 26057 26058 26059
R29 26060 26061 26062 26063 26064 26065 26066 26067 26068 26069 26482 26483 26484 26486 26487 26488 26489 26490 26491 26492 26493 26494 26495 26496 26497 26498 26499 26500 26501
R30 26502 26503 26504 26505 26506 26507 26508 26509 26510 26511 26512 26513 26514 26515 26516 26517 26518 26520 26521 26522 26523 26524 26525 26526 26527 26528 26529 26530 26531
1-C1 1-C2 1-C3 1-C4 1-C5 1-C6 1-C7 1-C8 1-C9 1-C10 1-C11 1-C12 1-C13 1-C14 1-C15 2-C1 2-C2 2-C3 2-C4 2-C5 2-C6 2-C7 2-C8 2-C9 2-C10 2-C11 2-C12 2-C13 2-C14 2-C15
1-R1 25310 25311 25312 25313 25314 25315 25316 25317 25318 25319 25320 25321 25322 25323 25324 2-R1 25220 25221 25222 25223 25224 25225 25226 25227 25228 25229 25230 25231 25232 25233 25234
1-R2 25325 25326 25327 25328 25329 25330 25331 25332 25333 25334 25335 25336 25337 25338 27465 2-R2 25235 25236 25237 25238 25239 25240 25241 25242 25243 25244 25245 25248 27464
1-R3 25339 25340 25341 25342 25343 25344 25345 25346 25347 25348 25349 25350 25351 25352 25353 2-R3 25278 25279 25280 25281 25282 25283 25285 25286 25288 25289 25290 25291 25292 25293 25295
1-R4 25354 25355 25356 25357 25358 25359 25360 25361 25362 25363 25364 25365 25366 27466 2-R4 25296 25297 25298 25299 25300 25301 25302 25303 25304 25305 25306 25307 25308 25309
1-R5 25396 25397 25398 25399 25400 25401 25402 25406 25407 25412 25413 25414 25415 25416 25417 2-R5 25249 25250 25251 25252 25253 25254 25255 25256 25257 25258 25259 25260 25261 25262 25263
1-R6 25418 25419 25420 25421 25422 25423 25425 25426 25427 25428 25429 25430 25431 25432 2-R6 25264 25265 25266 25267 25268 25269 25270 25271 25272 25273 25274 25275 25276 25277
1-R7 25433 25434 25435 25436 25437 25438 25439 25440 25441 25442 25443 25444 25445 25446 25447 2-R7 25367 25368 25369 25370 25371 25372 25373 25374 25375 25376 25377 25378 25379 25380 25381
1-R8 25448 25449 25450 25451 25452 25453 25456 25457 25458 25459 25460 25461 25462 25463 27468 2-R8 25382 25383 25384 25385 25386 25387 25388 25389 25390 25391 25392 25393 25394 25395
1-R9 25855 25856 25857 25858 25859 25860 25861 25862 25863 25864 25865 25866 25867 25868 25869 2-R9 25464 25465 25466 25467 25468 25469 25470 25471 25472 25473 25474 25475 25476 25477 25478
1-R10 25870 25871 25872 25873 25874 25875 25876 25877 25878 25879 25880 25881 25882 25883 25715 2-R10 25479 25480 25481 25482 25483 25484 25485 25486 25487 25488 25489 25490 25491 27463
1-R11 25885 25886 25887 25888 25889 25890 25891 25892 25893 25894 25895 25896 25897 25898 25899 2-R11 25555 25556 25557 25558 25559 25560 25562 25563 25564 25565 25566 25568 25569 25570 25571
1-R12 25900 25901 25902 25903 25904 25905 25906 25907 25908 25909 25910 25911 25912 25913 26516 2-R12 25572 25573 25574 25575 25576 25577 25578 25579 25580 25581 25582 25583 25584 25585
1-R13 26001 26002 26003 26004 26005 26006 26007 26008 26009 26010 26011 26012 26013 26014 2-R13 25778 25779 25782 25783 25784 25785 25786 25841 25842 25843 25844 25845 25846 27475 25686
1-R14 26016 26017 26018 26019 26020 26021 26022 26023 26024 26025 26026 26027 26028 26029 2-R14 25730 25731 25732 25733 25734 25735 25736 25737 25738 25739 25740 25741 25742 25743 25744
1-R15 25787 25788 25789 25790 25791 25848 25849 25850 25851 25852 26015 27479 2-R15 25745 25746 25747 25748 25749 25750 25751 25752 27477 25753 25754 25755 25756 25757 25847
3-C1 3-C2 3-C3 3-C4 3-C5 3-C6 3-C7 3-C8 3-C9 3-C10 3-C11 3-C12 3-C13 3-C14 3-C15 4-C1 4-C2 4-C3 4-C4 4-C5 4-C6 4-C7 4-C8 4-C9 4-C10 4-C11 4-C12 4-C13 4-C14
3-R1 25492 25493 25494 25495 25496 25497 25498 25499 25500 25501 25502 25503 25505 25506 25507 4-R1 25524 25525 25526 25527 25528 25529 25530 25531 25532 25533 25534 25536 25537 25538
3-R2 25508 25509 25512 25513 25514 25515 25516 25517 25518 25519 25520 25521 25522 25523 25539 4-R2 25540 25541 25542 25545 25546 25547 25548 25549 25550 25551 25552 25553 25554 25853
3-R3 25914 25915 25916 25917 25918 25919 25920 25921 25922 25923 25924 25925 25926 25927 25928 4-R3 25586 25587 25588 25589 25590 25591 25592 25593 25594 25595 25596 25597 25598 25599
3-R4 25929 25930 25931 25932 25933 25934 25935 25936 25937 25938 25939 25940 25941 25942 27480 4-R4 25600 25601 25602 25603 25604 25605 25606 25607 25608 25609 25610 25611 25612 25613
3-R5 25943 25944 25945 25946 25947 25948 25949 25950 25951 25952 25953 25954 25955 25956 25957 4-R5 25614 25615 25616 25617 25618 25619 25620 25621 25622 25623 25624 25625 25626 25627
3-R6 25958 25959 25960 25961 25962 25963 25964 25965 25966 25967 25968 25969 25970 25971 25854 4-R6 25629 25630 25631 25632 25633 25634 25635 25636 25637 25638 25639 25640 25641 25642
3-R7 25972 25973 25974 25975 25976 25977 25978 25979 25980 25981 25982 25983 25984 25985 25986 4-R7 25643 25644 25645 25646 25647 25648 25649 25650 25651 25652 25653 25654 25655 25656
3-R8 25987 25988 25989 25990 25991 25992 25993 25994 25995 25996 25997 25998 25999 26000 27471 4-R8 25658 25659 25660 25661 25662 25663 25664 25665 25666 25667 25668 25669 25670 25671
3-R9 26030 26031 26032 26033 26035 26036 26037 26038 26039 26040 26041 26042 26043 26044 26045 4-R9 25672 25673 25674 25675 25676 25677 25678 25679 25680 25681 25682 25683 25684 25685
3-R10 26046 26047 26048 26049 26050 26051 26052 26053 26054 26055 26056 26057 26058 26059 4-R10 25687 25688 25689 25690 25691 25692 25693 25694 25695 25696 25697 25698 25699 25700
3-R11 26060 26061 26062 26063 26064 26065 26066 26067 26068 26069 26482 26483 26484 26486 26487 4-R11 25701 25702 25703 25704 25705 25706 25707 25708 25709 25710 25711 25712 25713 25714
3-R12 26488 26489 26490 26491 26492 26493 26494 26495 26496 26497 26498 26499 26500 26501 27473 4-R12 25716 25717 25718 25719 25720 25721 25722 25723 25724 25725 25726 25727 25728 25729
3-R13 25792 25793 25794 25795 25796 25797 25798 25799 25801 25802 25803 25804 25805 25806 25628 4-R13 26502 26503 26504 26505 26506 26507 26508 26509 26510 26511 26512 26513 26514 26515
3-R14 25808 25810 25811 25812 25813 25814 25815 25816 25817 25818 25819 25820 25821 25822 27476 4-R14 26517 26518 26520 26521 26522 26523 26524 26525 26526 26527 26528 26529 26530 26531
3-R15 25769 25770 25771 25772 25775 25776 25777 25833 25834 25835 25837 25838 25839 25840 25657 4-R15 25762 25763 25764 25765 25766 25767 25768 25823 25824 25825 25829 25830 25831 25832
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Frank scores by different predictors of 120 unbiased epitopes
0.99636 0.98743 0.99755 0.99797 0.99631 0.99604 0.99562
0.00136 0.00180 0.00066 0.00040 0.00154 0.00125 0.00059
0.0001 <0.0001 0.0102 NA <0.0001 <0.0001 0.0156
Lymphocytes Singlets


























Stability                 
(t½; h)





YFV_pp61-69 CapsidC (61-69) ITAHLKRLW B*57:01 0.05 9.0 3/11 0.01-0.02
YFV_pp64-72 CapsidC (64-72) HLKRLWKML B*08:01 0.30 0.5 8/42 0.03-0.30
YFV_pp102-110 ER anchor (1-9) SHDVLTVQF B*38:01 0.40 1.6 7/7 0.02-0.20
YFV_pp103-110 ER anchor (2-9) HDVLTVQF B*37:01 3.00 19.4 2/2 0.02-0.50
YFV_pp331-339 EnvE (46-54) ETVAIDRPA A*68:02 0.18 15.8 2/2 0.10-0.40
YFV_pp453-460 EnvE (168-175) QEVEFIGY B*18:01 0.08 4.1 13/14 0.01-0.70
YFV_pp471-479 EnvE (186-194) TAVDFGNSY B*35:01 0.25 2.7 9/23 0.01-0.10
YFV_pp485-494 EnvE (200-209) TESWIVDRQW B*44:02 0.15 NA 33/35 0.01-1.50 (PMID:28386132)1
YFV_pp485-494 EnvE (200-209) TESWIVDRQW B*44:03 0.13 NA 8/12 0.03-0.20
YFV_pp486-494 EnvE (201-209) ESWIVDRQW B*57:01 0.30 1.9 13/15 0.01-0.20
YFV_pp492-500 EnvE (207-215) RQWAQDLTL B*40:02 0.40 2.4 2/7 0.01-0.20
YFV_pp492-500 EnvE (207-215) RQWAQDLTL B*13:02 0.40 2.4 4/4 0.05-0.30 (PMID:28386132)1
YFV_pp500-510 EnvE (215-225) LPWQSGSGGVW B*53:01 0.03 NA 3/3 0.20-0.30
YFV_pp500-510 EnvE (215-225) LPWQSGSGGVW B*35:01 0.20 2.9 12/22 0.01-0.20
YFV_pp511-519 EnvE (226-234) REMHHLVEF B*37:01 0.03 19.8 3/3 0.01-0.30
YFV_pp511-519 EnvE (226-234) REMHHLVEF B*40:01 0.05 1.5 19/30 0.01-0.80
YFV_pp517-525 EnvE (232-240) VEFEPPHAA B*40:02 0.80 12.1 6/7 0.01-0.10
YFV_pp517-525 EnvE (232-240) VEFEPPHAA B*50:01 0.10 3.8 2/3 0.10-0.20
YFV_pp569-577 EnvE (284-292) RVKLSALTL B*07:02 1.50 4.8 5/41 0.03-0.40 (PMID: 22039500)2
YFV_pp569-578 EnvE (284-293) RVKLSALTLK A*03:01 0.25 36.3 29/39 0.01-0.20
YFV_pp651-660 EnvE (366-375) EVNPPFGDSY A*25:01 0.13 3.1 2/11 0.03-0.10
YFV_pp651-660 EnvE (366-375) EVNPPFGDSY A*26:01 0.13 1.5 3/10 0.02-0.03
YFV_pp729-737 EnvE (444-452) GLFGGLNWI A*02:01 0.30 5.1 12/89 0.01-0.10 (PMID: 22039500)2
YFV_pp759-767 EnvE (474-482) SMSMILVGV A*02:01 0.30 16.4 27/95 0.01-0.10
YFV_pp802-810 NS1 (24-32) DSDDWLNKY A*01:01 0.05 1.4 40/53 0.01-0.20
YFV_pp883-891 NS1 (105-113) SRIRDGLQY B*27:02 0.80 9.0 1/1 0.05-0.05
YFV_pp884-893 NS1 (106-115) RIRDGLQYGW A*32:01 0.40 107.9 15/18 0.02-0.10
YFV_pp884-893 NS1 (106-115) RIRDGLQYGW B*57:01 0.40 6.3 9/15 0.01-0.10
YFV_pp885-893 NS1 (107-115) IRDGLQYGW B*27:02 1.00 2.4 1/1 0.40-0.40
YFV_pp894-902 NS1 (116-124) KTWGKNLVF A*32:01 0.03 32.1 19/19 0.10-2.80 (PMID:28386132)1
YFV_pp894-902 NS1 (116-124) KTWGKNLVF B*58:01 0.25 9.3 3/3 0.20-0.40
YFV_pp894-902 NS1 (116-124) KTWGKNLVF B*57:01 0.10 5.3 14/15 0.02-0.80 (PMID:25674793)1
YFV_pp945-953 NS1 (167-175) VYMDAVFEY A*29:02 0.08 39.1 3/9 0.03-0.10
YFV_pp945-953 NS1 (167-175) VYMDAVFEY A*24:02 0.80 32.8 7/33 0.01-0.20 (PMID 23338234)3
YFV_pp970-978 NS1 (192-200) KSAHGSPTF B*58:01 0.13 13.7 2/3 0.10-0.10
YFV_pp983-991 NS1 (205-213) HEVNGTWMI B*40:01 0.13 1.2 2/31 0.02-0.03
YFV_pp1002-1010 NS1 (224-232) CEWPLTHTI B*49:01 0.01 11.7 2/3 0.05-0.05
YFV_pp1002-1010 NS1 (224-232) CEWPLTHTI B*40:01 0.40 0.9 6/26 0.02-0.80
YFV_pp1114-1123 NS1 (336-345) RPRKTHESHL B*07:02 0.03 4.8 19/44 0.01-0.20
YFV_pp1114-1124 NS1 (336-346) RPRKTHESHLV B*07:02 0.10 3.0 12/44 0.01-0.20
YFV_pp1119-1127 NS1 (341-349) HESHLVRSW B*44:02 0.05 NA 30/33 0.02-0.40
YFV_pp1119-1127 NS1 (341-349) HESHLVRSW B*44:03 0.05 NA 9/13 0.10-0.30
YFV_pp1131-1140 NS2A (1-10) GEIHAVPFGL B*40:01 0.01 1.5 22/28 0.01-0.50
YFV_pp1131-1141 NS2A (1-11) GEIHAVPFGLV B*40:01 0.25 1.2 13/31 0.01-0.30
YFV_pp1134-1143 NS2A (4-13) HAVPFGLVSM B*35:08 0.80 13.5 2/2 1.30-9.70 (PMID: 11853408)4; (PMID:19740333)5
YFV_pp1134-1143 NS2A (4-13) HAVPFGLVSM B*35:03 0.80 7.7 6/6 0.20-4.50 (PMID: 11853408)4; (PMID:19740333)5
YFV_pp1134-1143 NS2A (4-13) HAVPFGLVSM B*35:01 0.40 7.0 22/24 0.10-1.70 (PMID: 11853408)
4; (PMID:19740333)5; 
(PMID:28386132)1
YFV_pp1200-1207 NS2A (70-77) DAMYMALI B*51:01 0.80 17.3 13/18 0.03-2.20
YFV_pp1227-1234 NS2A (97-104) SPRERLVL B*07:02 0.01 4.1 4/44 0.01-0.02
YFV_pp1227-1236 NS2A (97-106) SPRERLVLTL B*07:02 0.03 1.8 40/44 0.02-4.00
YFV_pp1317-1325 NS2A (187-195) SMQKTIPLV A*02:01 0.80 27.3 43/95 0.01-0.10
YFV_pp1397-1405 NS2B (43-51) SVAGRVDGL A*02:05 4.00 18.7 5/5 0.02-0.40
YFV_pp1464-1472 NS2B (110-118) HPFALLLVL B*35:01 0.30 5.9 22/23 0.05-0.90 (PMID: 11853408)
4; (PMID:19740333)5; 
(PMID:28386132)1
YFV_pp1464-1472 NS2B (110-118) HPFALLLVL B*35:03 0.13 5.9 5/6 0.20-0.80 (PMID: 11853408)
4; (PMID:19740333)5; 
(PMID:28386132)1
YFV_pp1471-1479 NS2B (117-125) VLAGWLFHV A*02:01 0.01 27.7 75/86 0.01-0.50 (PMID: 22039500)2
YFV_pp1488-1496 NS3 (4-12) VLWDIPTPK A*11:01 0.50 9.0 16/28 0.01-0.20
YFV_pp1488-1496 NS3 (4-12) VLWDIPTPK A*03:01 0.18 6.2 31/40 0.01-0.40 (PMID:28386132)1
YFV_pp1508-1516 NS3 (24-32) IYGIFQSTF A*24:02 0.08 40.7 22/33 0.01-1.00 (PMID:28386132)1
YFV_pp1508-1516 NS3 (24-32) IYGIFQSTF A*23:01 0.13 40.6 4/5 0.01-0.20
YFV_pp1557-1565 NS3 (73-81) SVKEDLVAY B*15:01 0.80 14.5 28/30 0.03-1.10 (PMID:28386132)1
YFV_pp1557-1565 NS3 (73-81) SVKEDLVAY B*35:01 1.50 3.2 13/23 0.01-0.10 (PMID:28386132)1
YFV_pp1608-1615 NS3 (124-131) GEIGAVAL B*40:01 0.01 3.2 5/17 0.02-0.10
YFV_pp1632-1641 NS3 (148-157) EVIGLYGNGI A*68:02 0.50 2.9 1/2 0.04-0.04
YFV_pp1635-1643 NS3 (151-159) GLYGNGILV A*02:01 1.50 20.1 27/80 0.01-0.20 (PMID: 22039500)2
YFV_pp1690-1697 NS3 (206-213) RRFLPQIL C*06:02 0.15 1.4 6/28 0.10-2.78
YFV_pp1689-1697 NS3 (205-213) TRRFLPQIL C*06:02 8.00 17.7 27/28 0.02-1.90
YFV_pp1702-1710 NS3 (218-226) RRRLRTLVL B*14:02 0.15 0.9 4/4 0.05-0.40 (PMID: 18762226)6
YFV_pp1718-1727 NS3 (234-243) SEMKEAFHGL B*40:01 0.05 1.3 16/29 0.01-0.40
YFV_pp1728-1736 NS3 (244-252) DVKFHTQAF A*25:01 0.15 3.2 10/11 0.02-0.30 (PMID: 18762226)6
YFV_pp1770-1778 NS3 (286-294) IIMDEAHFL A*02:05 0.20 20.7 5/5 0.10-0.70
YFV_pp1770-1778 NS3 (286-294) IIMDEAHFL A*02:01 0.50 9.2 43/93 0.01-0.10 (PMID: 22039500)2
YFV_pp1777-1785 NS3 (293-301) FLDPASIAA A*02:01 0.40 9.9 56/84 0.01-0.70
YFV_pp1831-1839 NS3 (347-355) EPWNTGHDW B*53:01 0.10 NA 2/3 0.10-0.10
YFV_pp1910-1918 NS3 (426-434) RVLDCRTAF A*32:01 0.80 31.1 4/19 0.05-0.10
YFV_pp1991-1999 NS3 (507-515) GMVAPLYGV A*02:01 0.10 9.4 37/96 0.01-0.20
YFV_pp2030-2039 NS3 (546-555) LPVWLSWQVA B*56:01 0.05 2.3 3/3 0.10-0.10
YFV_pp2060-2068 NS3 (576-584) ILNDSGETV A*02:01 1.50 12.2 42/92 0.01-0.40
YFV_pp2128-2136 NS4A (21-29) GEAMDTISV B*40:01 0.40 1.3 7/32 0.01-0.20
YFV_pp2129-2137 NS4A (22-30) EAMDTISVF B*35:01 0.10 3.7 3/21 0.01-0.03
YFV_pp2130-2138 NS4A (23-31) AMDTISVFL A*02:01 0.80 11.0 5/95 0.01-0.03 (PMID:27017899)
YFV_pp2152-2160 NS4A (45-53) SMMPEAMTI B*52:01 0.10 9.1 3/3 0.01-0.03
YFV_pp2154-2163 NS4A (47-56) MPEAMTIVML B*35:03 0.05 3.9 5/6 0.10-0.80
YFV_pp2154-2163 NS4A (47-56) MPEAMTIVML B*35:01 0.30 3.8 21/25 0.03-1.00
YFV_pp2154-2163 NS4A (47-56) MPEAMTIVML B*53:01 0.15 2.9 2/3 0.10-0.10
YFV_pp2155-2163 NS4A (48-56) PEAMTIVML B*40:01 1.00 ND 13/17 0.10-0.80
YFV_pp2180-2189 NS4A (73-82) SPKGISRMSM B*07:02 0.10 8.6 29/43 0.01-0.10
YFV_pp2389-2397 NS4B (133-141) KLAQRRVFH A*03:01 1.00 8.6 26/32 0.01-1.40
YFV_pp2421-2429 NS4B (165-173) ALYEKKLAL A*02:01 2.00 19.2 3/85 0.01-0.50
YFV_pp2421-2429 NS4B (165-173) ALYEKKLAL B*08:01 0.25 0.4 28/41 0.01-0.20
YFV_pp2423-2431 NS4B (167-175) YEKKLALYL B*40:02 0.40 24.4 7/7 0.04-0.60
YFV_pp2423-2431 NS4B (167-175) YEKKLALYL B*40:01 0.30 1.1 4/28 0.03-0.30
YFV_pp2470-2478 NS4B (214-222) LLWNGPMAV A*02:01 0.13 38.2 98/98 0.03-11.50 (PMID 19933869)
YFV_pp2494-2502 NS4B (238-246) VMYNLWKMK A*03:01 0.05 0.8 17/38 0.01-2.40
YFV_pp2524-2533 NS5 (18-27) LLDKRQFELY A*01:01 0.05 11.7 32/52 0.01-0.20
YFV_pp2571-2579 NS5 (65-73) FHERGYVKL B*38:01 0.10 5.2 7/7 0.10-0.60
YFV_pp2571-2579 NS5 (65-73) FHERGYVKL B*39:01 0.15 0.6 5/6 0.10-1.00
YFV_pp2669-2677 NS5 (163-171) RVLDTVEKW A*32:01 0.80 101.6 11/19 0.01-0.10
YFV_pp2669-2677 NS5 (163-171) RVLDTVEKW B*58:01 0.13 32.9 2/3 0.10-0.40
YFV_pp2669-2677 NS5 (163-171) RVLDTVEKW B*57:01 0.15 16.2 13/15 0.01-0.20
YFV_pp2706-2714 NS5 (200-208) RRFGGTVIR B*27:05 0.05 22.9 6/12 0.02-0.10
YFV_pp2711-2719 NS5 (205-213) TVIRNPLSR A*68:01 0.50 11.9 11/19 0.03-0.70
YFV_pp2723-2731 NS5 (217-225) HEMYYVSGA B*50:01 0.08 NA 3/3 0.04-0.10
YFV_pp2762-2770 NS5 (256-264) DVILPIGTR A*68:01 0.50 37.4 20/20 0.01-0.90
YFV_pp2792-2801 NS5 (286-295) KSEYMTSWFY A*01:01 0.08 44.2 50/52 0.01-4.60 (PMID:28386132)1
YFV_pp2854-2862 NS5 (348-356) TPFGQQRVF B*35:01 0.40 3.6 8/22 0.01-0.10
YFV_pp2879-2887 NS5 (373-381) KIMKVVNRW B*58:01 0.18 19.2 1/3 0.01-0.01
YFV_pp2882-2890 NS5 (376-384) KVVNRWLFR A*03:01 0.40 6.5 2/38 0.02-0.03
YFV_pp2974-2982 NS5 (468-476) KAKGSRAIW B*57:01 0.13 11.2 10/15 0.01-0.10
YFV_pp2977-2985 NS5 (471-479) GSRAIWYMW B*57:01 0.08 9.1 5/15 0.01-0.02
YFV_pp2981-2990 NS5 (475-484) IWYMWLGARY A*29:02 0.10 0.6 2/8 0.10-0.20
YFV_pp2982-2990 NS5 (476-484) WYMWLGARY A*29:02 0.25 24.7 8/9 0.10-0.50 (PMID:28386132)1
YFV_pp2983-2990 NS5 (477-484) YMWLGARY A*29:02 0.03 3.0 3/9 0.03-0.30
YFV_pp2983-2990 NS5 (477-484) YMWLGARY A*01:01 1.50 67.3 47/52 0.01-0.80
YFV_pp3024-3032 NS5 (518-526) YVIRDLAAM B*35:01 0.13 5.9 16/20 0.01-0.10
YFV_pp3063-3071 NS5 (557-565) YMSPHHKKL A*02:05 1.50 16.9 4/5 0.10-0.20
YFV_pp3178-3186 NS5 (672-680) RPIDDRFGL B*07:02 0.15 6.3 45/45 0.01-0.80 (PMID: 23338234)3; (PMID: 28386132)1
YFV_pp3178-3187 NS5 (672-681) RPIDDRFGLA B*07:02 0.80 3.1 8/46 0.01-0.50
YFV_pp3178-3188 NS5 (672-682) RPIDDRFGLAL B*07:02 0.03 2.5 41/47 0.01-0.60
YFV_pp3178-3188 NS5 (672-682) RPIDDRFGLAL B*35:03 0.25 3.5 3/6 0.01-0.10
YFV_pp3389-3399 NS5 (883-893) YTDYLTVMDRY A*01:01 0.01 42.0 48/53 0.06-0.70
Table SI. A complete list of the 120 peptide-specific, HLA-I-restricted CD8+ T cell epitopes identified by the HFRI approach.
The HFRI-based CD8+ T cell epitope discovery process detailed for donor YF1067 was extended to 50 randomely selected, primary YFV-vaccinated donors. Ninety-two different epitopes 
restricted by 40 HLA-I allotypes were discovered. The peptide-HLA-I affinity was predicted by NetMHCpan 2.4 (given in %Rank; the lower, the better); the stability was measured (given as 
half-life at 37oC in hours; the longer, the better). Productively interaction peptide-HLA-I combinations were used to design peptide-HLA-I tetramers. the resulting tetramers were used to stain 
and ex vivo analyze CD8+ T cells by flow cytometry gating on CD3+ CD8+ T cells. The prevalence of these responses is given as "the number of positive donors/the number of donors tested". 
The magnitudes are given as the range of frequencies (in %) of ex vivo  tetramer-stained CD8+ T cells. Note, that for the prevalence and magnitude measurements, the specific responses 
identified in 50 vaccinees was extended to additional donors within our cohort of primary vaccinee, who expressed the relevant HLA-I allotype. 
PubMed ID (PMID) references are given in the event that an epitope had been reported before this study.
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YFV_pp438-446 EnvE (153-161) NTDIKTLKF A*01:01 0.15 1.70 46/51 0.02-0.90
YFV_pp511-519 EnvE (226-234) REMHHLVEF B*40:02 0.03 17.7 3/7 0.01-0.02
YFV_pp1131-1140 NS2A (1-10) GEIHAVPFGL B*40:02 0.05 11.8 5/7 0.03-0.10
YFV_pp1504-1512 NS3 (20-28) LEDGIYGIF B*40:01 0.4 2.30 6/27 0.01-0.10
YFV_pp2762-2770 NS5 (256-264) DVILPIGTR A*33:01 0.18 NA 2/2 0.01-0.10
YFV_pp3024-3032 NS5 (518-526) YVIRDLAAM A*26:01 0.01 10.6 7/10 0.01-0.30
YFV_pp3089-3098 NS5 (583-592) RPAPGGKAYM B*07:02 0.03 8.5 22/44 0.01-0.20
YFV_pp3116-3124 NS5 (610-618) ALNTITNLK A*03:01 0.10 14.8 12/33 0.01-0.10
YFV_pp3268-3276 NS5 (762-770) YANMWSLMY B*35:01 0.30 8.6 7/22 0.01-0.10
Supplementary Table SII. CD8+ T cell epitopes derived from past epitope discovery efforts.
A panel of 533 YFV-derived peptides obtained from past epitope discovery efforts were evaluated by NetMHCpan 2.4 in an effort to 
discover additional CD8+ T cell epitopes. The stability of predicted peptide-HLA-I binders were verified experimentally. An 
additional 90 peptide-HLA-I tetramers could be generated and tested in appropriate primary YFV-vaccinated donors. Additionally 9 
epitopes and their restriction elements were identified. The prevalence and response magnitude of the corresponding CD8+ T cell 
responses were evaluated as descibed in Supplementary Table SI.
Predicted Measured 
Protein Position Sequence %Rank Stability(T½, h)




NS2A (97-104) SPRERLVL 0.01 4.1 4/44 Yes1
NS1 (243-251) MPRSIGGPV 0.03 4.6 0/18
NS2A (97-106) SPRERLVLTL 0.03 1.8 40/44 Yes1
NS5 (672-682) RPIDDRFGLAL 0.03 2.5 41/47 Yes
NS1 (336-345) RPRKTHESHL 0.03 4.8 19/44 Yes
NS5 (583-592) RPAPGGKAYM 0.03 8.5 22/44 No
NS4B (163-173) MPALYEKKLAL 0.05 2.0 0/16
CapsidC (15-23) MVRRGVRSL 0.05 3.3 0/16
NS5 (112-119) KPMNVQSL 0.05 3.4 0/18
NS5 (246-253) RPTGKVTL 0.08 6.5 0/18
NS1 (336-346) RPRKTHESHLV 0.10 3.0 12/44 Yes
NS4A (73-82) SPKGISRMSM 0.10 8.6 29/43 Yes2
NS4A (47-55) MPEAMTIVM 0.10 0.8 0/17 Yes3
NS4B (218-228) GPMAVSMTGVM 0.10 14.4 0/16
NS3 (133-142) YPSGTSGSPI 0.10 2.5 0/17
prM (128-136) NPFFAVTAL 0.12 2.3 0/18
NS3 (367-376) LPSIRAANVM 0.12 5.7 0/18
NS4B (107-117) MPLLCGIGCAM 0.12 3.5 0/18
NS1 (102-111) HPFSRIRDGL 0.12 3.0 0/16
NS5 (672-680) RPIDDRFGL 0.15 6.3 45/45 Yes
NS5 (559-569) SPHHKKLAQAV 0.15 1.4 0/18
NS5 (259-266) LPIGTRSV 0.17 0.7 0/18 Yes
NS3 (199-209) HPGAGKTRRFL 0.20 1.6 0/17
NS2B (110-118) HPFALLLVL 0.20 NF ND
NS5 (710-720) VPFCSHHFHEL 0.25 3.9 0/18
NS4A (100-108) KPTHISYVM 0.25 6.5 0/18
NS1 (266-273) GPWMQVPL 0.25 0.4 0/18
NS5 (185-192) APYMPDVL 0.25 6.4 0/18
NS3 (361-370) RPTAWFLPSI 0.25 1.7 0/17
NS1 (226-236) WPLTHTIGTSV 0.25 2.6 0/18
NS5 (583-590) RPAPGGKA 0.25 NA ND
EnvE (52-59) RPAEVRKV 0.25 NA ND
NS4A (47-56) MPEAMTIVML 0.30 NA 0/18 Yes3
NS3 (588-596) APGGAKKPL 0.30 13.5 0/18
NS3 (308-318) RARANESATIL 0.30 3.7 0/18
NS5 (209-219) NPLSRNSTHEM 0.30 2.6 0/18
NS4B (84-93) IPFMKMNISV 0.30 NA ND
NS4B (84-94) IPFMKMNISVI 0.30 NA ND
NS2A (6-13) VPFGLVSM 0.30 0.4 0/16
CapsidC (37-44) RPGPSRGV 0.30 NA ND
EnvE (38-45) KPSLDISL 0.40 NA ND
NS4A (73-80) SPKGISRM 0.40 1.4 0/18 Yes2
NS1 (125-133) SPGRKNGSF 0.40 2.7 0/18
NS3 (227-236) APTRVVLSEM 0.40 5.3 0/18
NS1 (143-153) CPFSNRVWNSF 0.40 1.0 0/16
NS4B (51-58) SPMLHHWI 0.40 NA ND
NS1 (243-252) MPRSIGGPVS 0.40 NA ND
NS5 (583-591) RPAPGGKAY 0.40 6.2 0/18
CapsidC 37-47) RPGPSRGVQGF 0.40 NA ND
NS2B (71-78) SARYDVAL 0.40 NA ND
PrM (83-89)) RSRRSRRAI 0.40 NA ND
NS2B (92-102) VPWDQVVMTSL 0.40 NA ND
NS4B (205-214) GPLIEGNTSL 0.40 1.7 0/17
EnvE ((52-60) RPAEVRKVC 0.40 NA ND
NS5 672-681) RPIDDRFGLA 0.80 3.1 8/46 Yes
EnvE (284-292) RVKLSALTL 1.50 4.8 5/41 Yes
Note: HFRI suffix means that the peptides with the same suffix (1, 2 or 3) were found within the same 15mer peptide
T cell analysis
Table SIII. "hybrid forward-reverse immunology" vs "reverse immunology" approaches to HLA-B*07:02-restricted T 
cell epitope discovery.
NetMHCpan 2.4 was used to identify YFV-derived peptides predicted to bind with a high affinity to HLA-B*07:02 (threshold 
<0.5% Rank), and a selection of these were tested  experimentally for their stability of HLA-B*07:02 binding, their ability to 
support peptide-HLA-B*07:02 tetramer generation, and their ability to stain CD8+ T cells obtained ex vivo  from YFV vaccinees.
Proteom position Protein position Sequence Positive donorsof 50 tested
YFV_pp9-23 Capsid C (9-23) KTLGVNMVRRGVRSL 3
YFV_pp13-27 Capsid C (13-27) VNMVRRGVRSLSNKI 9
YFV_pp17-31 Capsid C (17-31) RRGVRSLSNKIKQKT 14
YFV_pp49-63 Capsid C (49-63) FFFLFNILTGKKITA 11
YFV_pp53-67 Capsid C (53-67) FNILTGKKITAHLKR 9
YFV_pp57-71 Capsid C (57-71) TGKKITAHLKRLWKM 3
YFV_pp61-75 Capsid C (61-75) ITAHLKRLWKMLDPR 4
YFV_pp65-79 Capsid C (65-79) LKRLWKMLDPRQGLA 6
YFV_pp73-87 Capsid C (73-87) DPRQGLAVLRKVKRV 4
YFV_pp77-91 Capsid C (77-91) GLAVLRKVKRVVASL 4
YFV_pp81-95 Capsid C (81-95) LRKVKRVVASLMRGL 10
YFV_pp85-99 Capsid C (85-99) KRVVASLMRGLSSRK 2
YFV_pp121-135 prM (1-14) GVTLVRKNRWLLLNV 1
YFV_pp125-139 prM (4-18) VRKNRWLLLNVTSED 1
YFV_pp133-147 prM (12-26) LNVTSEDLGKTFSVG 1
YFV_pp201-215 prM (80-94) SAGRSRRSRRAIDLP 1
YFV_pp205-219 prM (84-98) SRRSRRAIDLPTHEN 2
YFV_pp213-227 prM (92-106) DLPTHENHGLKTRQE 1
YFV_pp217-231 prM (96-110) HENHGLKTRQEKWMT 1
YFV_pp221-235 prM (100-114) GLKTRQEKWMTGRMG 1
YFV_pp237-251 prM (116-130) RQLQKIERWFVRNPF 2
YFV_pp245-259 prM (124-138) WFVRNPFFAVTALTI 1
YFV_pp249-263 prM (128-142KK) NPFFAVTALTIAYLVKK 3
YFV_pp253-267 prM (132-146K) AVTALTIAYLVGSNMK 4
YFV_pp257-271 prM (136-150KK) KKLTIAYLVGSNMTQRV 1
YFV_pp265-279 prM (144-158KK) SNMTQRVVIALLVLAKK 1
YFV_pp285-299 EnvE (1-13) SAHCIGITDRDFIEG 1
YFV_pp301-315 EnvE (16-30) HGGTWVSATLEQDKC 2
YFV_pp329-343 EnvE (44-58) SLETVAIDRPAEVRK 22
YFV_pp333-347 EnvE (48-62) VAIDRPAEVRKVCYN 5
YFV_pp341-355 EnvE (56-70) VRKVCYNAVLTHVKI 6
YFV_pp345-359 EnvE (60-74) CYNAVLTHVKINDKC 4
YFV_pp409-423 EnvE (124-138) SMSLFEVDQTKIQYV 4
YFV_pp413-427 EnvE (128-142) FEVDQTKIQYVIRAQ 6
YFV_pp417-431 EnvE (132-146) QTKIQYVIRAQLHVG 4
YFV_pp421-435 EnvE (136-150) QYVIRAQLHVGAKQE 9
YFV_pp489-503 EnvE (204-218) IVDRQWAQDLTLPWQ 2
YFV_pp493-507 EnvE (208-222) QWAQDLTLPWQSGSG 1
YFV_pp505-519 EnvE (220-234) GSGGVWREMHHLVEF 2
YFV_pp509-523 EnvE (224-238) VWREMHHLVEFEPPH 3
YFV_pp525-539 EnvE (240-254) ATIRVLALGNQEGSL 3
YFV_pp537-551 EnvE (252-266) GSLKTALTGAMRVTK 1
YFV_pp553-567 EnvE (268-282) TNDNNLYKLHGGHVS 1
YFV_pp557-571 EnvE (272-286) NLYKLHGGHVSCRVK 9
YFV_pp573-587 EnvE (288-302) SALTLKGTSYKICTD 2
YFV_pp589-603 EnvE (304-318) MFFVKNPTDTGHGTV 4
YFV_pp601-615 EnvE (316-330) GTVVMQVKVSKGAPC 4
YFV_pp613-627 EnvE (328-342) APCRIPVIVADDLTA 1
YFV_pp625-639 EnvE (340-354) LTAAINKGILVTVNP 3
YFV_pp629-643 EnvE (344-358) INKGILVTVNPIAST 1
YFV_pp669-683 EnvE (384-398) RLTYQWHKEGSSIGK 2
YFV_pp673-687 EnvE (388-402) QWHKEGSSIGKLFTQ 6
YFV_pp681-695 EnvE (396-410) IGKLFTQTMKGVERL 4
YFV_pp733-747 EnvE (KK448-462) KKGLNWITKVIMGAVLI 1
YFV_pp745-759 EnvE (460-474K) VLIWVGINTRNMTMSK 3
YFV_pp809-823 NS1 (31-45) KYSYYPEDPVKLASI 3
YFV_pp841-855 NS1 (63-77) LEHEMWRSRADEINA 3
YFV_pp845-859 NS1 (67-81) MWRSRADEINAIFEE 4
YFV_pp849-863 NS1 (71-85) RADEINAIFEENEVD 4
YFV_pp865-879 NS1 (87-101) SVVVQDPKNVYQRGT 7
YFV_pp889-903 NS1 (111-125) LQYGWKTWGKNLVFS 4
YFV_pp893-907 NS1 (115-129) WKTWGKNLVFSPGRK 2
YFV_pp905-919 NS1 (127-140) GRKNGSFIIDGKSRK 2
YFV_pp909-923 NS1 (131-144) GSFIIDGKSRKECPF 4
YFV_pp921-935 NS1 (143-157) CPFSNRVWNSFQIEE 1
YFV_pp945-959 NS1 (167-181) VYMDAVFEYTIDCDG 2
YFV_pp953-967 NS1 (175-189) YTIDCDGSILGAAVND 2
YFV_pp985-999 NS1 (207-221) VNGTWMIHTLEALDY 5
YFV_pp989-1003 NS1 (211-225) WMIHTLEALDYKECE 3
YFV_pp1001-1015 NS1 (223-237) ECEWPLTHTIGTSVE 2
YFV_pp1005-1019 NS1 (227-241) PLTHTIGTSVEESEM 1
YFV_pp1085-1099 NS1 (307-321) VIPEWCCRSCTMPPV 1
YFV_pp1105-1119 NS1 (327-341) DGCWYPMEIRPRKTH 4
YFV_pp1129-1143 NS2A (1-13) TAGEIHAVPFGLVSM 1
YFV_pp1133-1147 NS2A (3-17KK) IHAVPFGLVSMMIAMKK 1
YFV_pp1141-1155 NS2A (11-25) VSMMIAMEVVLRKRQ 1
YFV_pp1177-1191 NS2A (47-61KK) KKTLLDLLKLTVAVGLH 4
YFV_pp1181-1195 NS2A (51-65) LLKLTVAVGLHFHEM 1
YFV_pp1197-1211 NS2A (KK67-80) KKNGGDAMYMALIAAFS 1
YFV_pp1217-1231 NS2A (87-101) LIGFGLRTLWSPRER 3
YFV_pp1229-1243 NS2A (99-113) RERLVLTLGAAMVEI 1
YFV_pp1233-1247 NS2A (103-117KK) VLTLGAAMVEIALGGKK 1
YFV_pp1245-1259 NS2A (115-129) LGGVMGGLWKYLNAV 1
YFV_pp1249-1263 NS2A (119-133) MGGLWKYLNAVSLCI 7
YFV_pp1253-1267 NS2A (123-137KK) KKWKYLNAVSLCILTIN 4
YFV_pp1337-1351 NS2A (207-221) QPFLGLCAFLATRIFK 1
YFV_pp1373-1387 NS2B (19-33) GLAFQEMENFLGPIA 1
YFV_pp1377-1391 NS2B (23-37) QEMENFLGPIAVGGL 1
YFV_pp1385-1399 NS2B (31-45KK) KKPIAVGGLLMMLVSVA 1
YFV_pp1485-1499 NS3 (1-15) SGDVLWDIPTPKIIE 2
YFV_pp1489-1503 NS3 (5-19) LWDIPTPKIIEECEH 1
YFV_pp1505-1519 NS3 (21-35) EDGIYGIFQSTFLGA 2
YFV_pp1529-1543 NS3 (45-59) GGVFHTMWHVTRGAF 1
YFV_pp1533-1547 NS3 (49-63) HTMWHVTRGAFLVRN 11
YFV_pp1537-1551 NS3 (53-67) HVTRGAFLVRNGKKL 1
YFV_pp1541-1555 NS3 (57-71) GAFLVRNGKKLIPSW 1
YFV_pp1581-1595 NS3 (97-111) VQLIAAVPGKNVVNV 1
YFV_pp1629-1643 NS3 (145-159) RNGEVIGLYGNGILV 2
YFV_pp1633-1647 NS3 (149-163) VIGLYGNGILVGDNS 6
YFV_pp1641-1655 NS3 (157-171) ILVGDNSFVSAISQT 1
YFV_pp1685-1699 NS3 (201-215) GAGKTRRFLPQILAE 4
YFV_pp1689-1703 NS3 (205-219) TRRFLPQILAECARR 5
YFV_pp1693-1707 NS3 (209-223) LPQILAECARRRLRT 8
YFV_pp1697-1711 NS3 (213-227) LAECARRRLRTLVLA 1
YFV_pp1701-1715 NS3 (217-231) ARRRLRTLVLAPTRV 1
YFV_pp1713-1727 NS3 (229-243) TRVVLSEMKEAFHGL 1
YFV_pp1737-1751 NS3 (253-267) SAHGSGREVIDAMCH 1
YFV_pp1753-1767 NS3 (269-283) TLTYRMLEPTRVVNW 4
YFV_pp1765-1779 NS3 (281-295) VNWEVIIMDEAHFLD 15
YFV_pp1769-1783 NS3 (285-299) VIIMDEAHFLDPASI 10
YFV_pp1773-1787 NS3 (289-303) DEAHFLDPASIAARG 1
YFV_pp1777-1791 NS3 (293-307) FLDPASIAARGWAAH 1
YFV_pp1797-1811 NS3 (313-327) ESATILMTATPPGTS 1
YFV_pp1821-1835 NS3 (337-351) IEDVQTDIPSEPWNT 3
YFV_pp1833-1847 NS3 (349-363) WNTGHDWILADKRPT 3
YFV_pp1837-1851 NS3 (353-367) HDWILADKRPTAWFL 16
YFV_pp1841-1855 NS3 (357-371) LADKRPTAWFLPSIR 2
YFV_pp1845-1859 NS3 (361-375) RPTAWFLPSIRAANV 2
YFV_pp1849-1863 NS3 (365-379) WFLPSIRAANVMAAS 10
YFV_pp1853-1867 NS3 (369-383) SIRAANVMAASLRKA 8
YFV_pp1861-1875 NS3 (377-391) AASLRKAGKSVVVLNK 1
YFV_pp1869-1883 NS3 (385-399) KSVVVLNRKTFEREY 4
YFV_pp1877-1891 NS3 (393-407) KTFEREYPTIKQKKP 4
YFV_pp1897-1911 NS3 (413-427) TDIAEMGANLCVERV 1
YFV_pp1929-1943 NS3 (445-459) VAIKGPLRISASSAA 1
YFV_pp1933-1947 NS3 (449-463) GPLRISASSAAQRRG 3
YFV_pp1941-1955 NS3 (457-471) SAAQRRGRIGRNPNR 2
YFV_pp1945-1959 NS3 (461-475) RRGRIGRNPNRDGDS 2
YFV_pp1957-1971 NS3 (473-487) GDSYYYSEPTSENNA 4
YFV_pp1961-1975 NS3 (477-491) YYSEPTSENNAHHVC 2
YFV_pp1969-1983 NS3 (485-499) NNAHHVCWLEASMLL 2
YFV_pp1973-1987 NS3 (489-503) HVCWLEASMLLDNME 1
YFV_pp1989-2003 NS3 (505-519) RGGMVAPLYGVEGTK 1
YFV_pp2021-2035 NS3 (537-551) FRELVRNCDLPVWLS 1
YFV_pp2029-2043 NS3 (545-559) DLPVWLSWQVAKAGL 2
YFV_pp2033-2047 NS3 (549-563) WLSWQVAKAGLKTND 1
YFV_pp2185-2199 NS4A (78-92) SRMSMAMGTMAGCGY 1
YFV_pp2189-2203 NS4A (82-96K) MAMGTMAGCGYLMFLK 2
YFV_pp2285-2299 NS4B (29-43) WPDLDLKPGAAWTVY 1
YFV_pp2289-2303 NS4B (33-47) DLKPGAAWTVYVGIV 3
YFV_pp2293-2307 NS4B (37-51K) GAAWTVYVGIVTMLSK 1
YFV_pp2297-2311 NS4B (41-55K) TVYVGIVTMLSPMLHK 5
YFV_pp2329-2343 NS4B (73-87) SASVLSFMDKGIPFM 1
YFV_pp2337-2351 NS4B (81-95K) DKGIPFMKMNISVIMK 4
YFV_pp2341-2355 NS4B (85-99KK) KKPFMKMNISVIMLLVS 1
YFV_pp2353-2367 NS4B (97-111) LVSGWNSITVMPLLC 4
YFV_pp2357-2371 NS4B (101-115KK) KKWNSITVMPLLCGIGC 1
YFV_pp2381-2395 NS4B (125-139) PGIKAQQSKLAQRRV 2
YFV_pp2385-2399 NS4B (129-143) AQQSKLAQRRVFHGV 1
YFV_pp2389-2403 NS4B (133-147 (E->K) KLAQRRVFHGVAKNP 5
YFV_pp2393-2407 NS4B (137-151 (E->K) RRVFHGVAKNPVVDG 4
YFV_pp2397-2411 NS4B (141-155 (E->K) HGVAKNPVVDGNPTV 1
YFV_pp2401-2415 NS4B (146-159) KNPVVDGNPTVDIEE 2
YFV_pp2405-2419 NS4B (149-163) VDGNPTVDIEEAPEM 1
YFV_pp2425-2439 NS4B (KK169-183) KKKKLALYLLLALSLAS 1
YFV_pp2437-2451 NS4B (181-195) LASVAMCRTPFSLAE 6
YFV_pp2481-2495 NS4B (225-239) TGVMRGNHYAFVGVM 1
YFV_pp2485-2499 NS4B (229-241) RGNHYAFVGVMYNLW 1
YFV_pp2489-2503 NS4B (233-247K) YAFVGVMYNLWKMKTK 10
YFV_pp2513-2527 NS5 (7-21) TLGEVWKRELNLLDK 2
YFV_pp2517-2531 NS5 (11-25) VWKRELNLLDKRQFE 1
YFV_pp2529-2543 NS5 (23-37) QFELYKRTDIVEVDR 4
YFV_pp2565-2579 NS5 (59-73) TAKLRWFHERGYVKL 2
YFV_pp2569-2583 NS5 (63-77) RWFHERGYVKLEGRV 1
YFV_pp2573-2587 NS5 (67-81) ERGYVKLEGRVIDLG 2
YFV_pp2677-2691 NS5 (171-185K) WLACGVDNFCVKVLAK 3
YFV_pp2833-2847 NS5 (327-341) KILTYPWDRIEEVTR 1
YFV_pp2877-2891 NS5 (371-385) TRKIMKVVNRWLFRH 11
YFV_pp2881-2895 NS5 (375-389) MKVVNRWLFRHLARE 3
YFV_pp2885-2899 NS5 (379-393) NRWLFRHLAREKNPR 3
YFV_pp2905-2919 NS5 (399-413) EFIAKVRSHAAIGAY 1
YFV_pp2957-2971 NS5 (451-465) CVYNMMGKREKKLSE 1
YFV_pp2977-2991 NS5 (471-485) GSRAIWYMWLGARYL 10
YFV_pp2981-2995 NS5 (475-489(KK) IWYMWLGARYLEFEAKK 8
YFV_pp2989-3003 NS5 (483-497) RYLEFEALGFLNEDH 1
YFV_pp3057-3071 NS5 (551-565) EQEILNYMSPHHKKL 5
YFV_pp3061-3075 NS5 (555-569) LNYMSPHHKKLAQAV 2
YFV_pp3069-3083 NS5 (563-577) KKLAQAVMEMTYKNK 1
YFV_pp3073-3087 NS5 (567-581) QAVMEMTYKNKVVKV 2
YFV_pp3077-3091 NS5 (571-585) EMTYKNKVVKVLRPA 2
YFV_pp3117-3131 NS5 (611-625) LNTITNLKVQLIRMA 3
YFV_pp3145-3159 NS5 (639-653(KK) KKCDESVLTRLEAWLTE 1
YFV_pp3205-3219 NS5 (699-713) QPSKGWNDWENVPFC 1
YFV_pp3213-3227 NS5 (707-727) WENVPFCSHHFHELQ 1
YFV_pp3277-3291 NS5 (771-785) FHKRDMRLLSLAVSS 3
YFV_pp3281-3295 NS5 (775-789) DMRLLSLAVSSAVPT 4
YFV_pp3313-3327 NS5 (807-821) WMTTEDMLEVWNRVW 1
YFV_pp3369-3383 NS5 (863-877) WASHIHLVIHRIRTL 2
YFV_pp3373-3387 NS5 (867-881) IHLVIHRIRTLIGQE 13
YFV_pp3377-3391 NS5 (871-885) IHRIRTLIGQEKYTD 9
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YFV_pp17-31  Capsid C (17-31) RRGVRSLSNKIKQKT DRB5*01:01 0.50 4 6/6
YFV_pp49-63  Capsid C (49-63) FFFLFNILTGKKITA DRB1*01:01 0.70 27 8/8
YFV_pp53-67  Capsid C (53-67)     FNILTGKKITAHLKR DRB1*01:01 6.50 7 8/8
YFV_pp65-79  Capsid C (65-79) LKRLWKMLDPRQGLA DRB1*01:01 4.50 15  5/5
YFV_pp73-87  Capsid C (73-87) DPRQGLAVLRKVKRV DRB1*13:01 0.12 4  1/1
YFV_pp73-87  Capsid C (73-87) DPRQGLAVLRKVKRV DRB1*13:02 32.00 5  5/5
YFV_pp77-91  Capsid C (77-91) GLAVLRKVKRVVASL DRB1*14:54 0.17 6 1/1
YFV_pp81-95  Capsid C (81-95) LRKVKRVVASLMRGL DRB1*07:01 0.70 7 5/5
YFV_pp81-95  Capsid C (81-95) LRKVKRVVASLMRGL DRB1*11:01 0.25 4 2/2
YFV_pp85-99  Capsid C (85-99)     KRVVASLMRGLSSRK DRB1*11:01 0.12 5 1/1
YFV_pp237-251  prM (116-130) RQLQKIERWFVRNPF DRB1*14:54 3.50 8 1/1
YFV_pp329-343  EnvE (44-58) SLETVAIDRPAEVRK DRB1*03:01 0.40 21 14/15
YFV_pp329-343  EnvE (44-58) SLETVAIDRPAEVRK DRB3*03:01 9.00 21  11/11
YFV_pp333-347  EnvE (48-62)     VAIDRPAEVRKVCYN DRB3*03:01 32.00 12  5/7
YFV_pp333-347  EnvE (48-62) VAIDRPAEVRKVCYN DRB1*03:01 11.00 15  4/5
YFV_pp341-355  EnvE (56-70) VRKVCYNAVLTHVKI DRB5*01:01 1.30 4 6/6
YFV_pp345-359  EnvE (60-74)     CYNAVLTHVKINDKC DRB5*01:01 7.00 9 5/5
YFV_pp417-431  EnvE (132-146) QTKIQYVIRAQLHVG DRB1*14:54 1.90 23 1/1
YFV_pp525-539  EnvE (240-254) ATIRVLALGNQEGSL DRB1*04:04 4.50 22 2/2
YFV_pp557-571  EnvE (272-286) NLYKLHGGHVSCRVK DRB1*13:02 44.00 9  7/7
YFV_pp673-687  EnvE (288-402) QWHKEGSSIGKLFTQ DRB1*04:01 43.00 567 2/2
YFV_pp601-615  EnvE (316-330) GTVVMQVKVSKGAPC DRB1*04:04 13.00 16 1/1
YFV_pp625-639  EnvE (340-354) LTAAINKGILVTVNP DRB3*03:01 1.50 2 5/5
YFV_pp865-879  NS1 (87-101) SVVVQDPKNVYQRGT DRB1*03:01 0.80 10 5/5
YFV_pp889-903  NS1 (111-125) LQYGWKTWGKNLVFS DRB1*13:01 6.50 6 1/1
YFV_pp889-903  NS1 (111-125) LQYGWKTWGKNLVFS DRB1*13:02 30.00 9 4/4
YFV_pp893-907  NS1 (115-129)     WKTWGKNLVFSPGRK DRB1*13:02 34.00 5 3/3
YFV_pp1105-1119  NS1 (327-341) DGCWYPMEIRPRKTH DRB5*01:01 1.50 2 8/8
YFV_pp1373-1387 NS2B (19-33) GLAFQEMENFLGPIA DRB1*15:01 16.00 42 1/1
YFV_pp1533-1547 NS3 (49-63) HTMWHVTRGAFLVRN DRB1*07:01 0.01 3  8/8
YFV_pp1541-1555 NS3 (57-71) GAFLVRNGKKLIPSW DRB1*13:01 0.06 2 1/1
YFV_pp1541-1555 NS3 (57-71) GAFLVRNGKKLIPSW DRB1*13:02 1.70 3 1/1
YFV_pp1541-1555 NS3 (57-71) GAFLVRNGKKLIPSW DRB1*14:54 2.50 6 1/1
YFV_pp1633-1647 NS3 (149-163) VIGLYGNGILVGDNS DRB1*15:01 18.00 14 4/4
YFV_pp1765-1779 NS3 (281-295) VNWEVIIMDEAHFLD DRB1*03:01 0.07 43 5/5
YFV_pp1769-1783 NS3 (285-299)     VIIMDEAHFLDPASI DRB1*03:01 0.10 13  6/6
YFV_pp1765-1779 NS3 (281-295) VNWEVIIMDEAHFLD DRB3*01:01 0.02 3  8/10
YFV_pp1769-1783 NS3 (285-299)     VIIMDEAHFLDPASI DRB3*01:01 0.08 8 1/1
YFV_pp1765-1779 NS3 (281-295) VNWEVIIMDEAHFLD DRB3*03:01 4.00 15 4/4
YFV_pp1769-1783 NS3 (285-299)     VIIMDEAHFLDPASI DRB3*03:01 6.00 11 4/4
YFV_pp1833-1847 NS3 (349-363) WNTGHDWILADKRPT DRB1*03:01 8.50 28 3/3
YFV_pp1837-1851 NS3 (353-367)     HDWILADKRPTAWFL DRB1*03:01 0.01 2 12/12
YFV_pp1849-1863 NS3 (365-379) WFLPSIRAANVMAAS DRB1*04:04 0.08 4 1/1
YFV_pp1853-1867 NS3 (369-383)     SIRAANVMAASLRKA DRB1*04:04 0.80 13 1/1
YFV_pp1877-1891 NS3 (393-407) KTFEREYPTIKQKKP DRB5*01:01 11.00 2 5/5
YFV_pp2021-2035 NS3 (537-551) FRELVRNCDLPVWLS DRB3*03:01 0.70 5 1/2
YFV_pp2337-2351 NS4B (81-95K) DKGIPFMKMNISVIMK DRB3*03:01 0.15 3 5/5
YFV_pp2401-2415 NS4B (146-159) KNPVVDGNPTVDIEE DRB3*03:01 44.00 7 5/5
YFV_pp2405-2419 NS4B (149-163)     VDGNPTVDIEEAPEM DRB3*03:01 90.00 22 5/5
YFV_pp2437-2451 NS4B (181-195) LASVAMCRTPFSLAE DRB1*04:04 0.04 2 1/1
YFV_pp2489-2503 NS4B (233-247K) YAFVGVMYNLWKMKTK DPA1*01:03-DPB1*04:01 5.00 NA  4/4
YFV_pp2565-2579 NS5 (59-73) TAKLRWFHERGYVKL DRB1*13:01 12.00 7 1/1
YFV_pp2565-2579 NS5 (59-73) TAKLRWFHERGYVKL DRB1*13:02 47.00 10 1/2
YFV_pp2565-2579 NS5 (59-73) TAKLRWFHERGYVKL DRB5*01:01 3.00 4 4/4
YFV_pp2569-2583 NS5 (63-77)     RWFHERGYVKLEGRV DRB5*01:01 5.50 5 1/1
YFV_pp2877-2891 NS5 (371-385) TRKIMKVVNRWLFRH DRB1*15:01 0.60 7 5/5
YFV_pp2905-2919 NS5 (399-413) EFIAKVRSHAAIGAY DRB1*15:01 1.20 2 1/1
YFV_pp2977-2991 NS5 (471-485) GSRAIWYMWLGARYL DRB1*01:01 6.50 6 8/8
YFV_pp2981-2995 NS5 (475-489KK)     IWYMWLGARYLEFEAKK DRB1*01:01 17.00 4 8/8
YFV_pp3057-3071 NS5 (551-565) EQEILNYMSPHHKKL DRB1*15:01 0.15 29  5/5
YFV_pp3057-3071 NS5 (551-565) EQEILNYMSPHHKKL DRB5*01:01 0.08 2  5/5
YFV_pp3061-3075 NS5 (555-569)     LNYMSPHHKKLAQAV DRB5*01:01 0.50 2  3/3
YFV_pp3373-3387 NS5 (867-881) IHLVIHRIRTLIGQE DRB1*04:04 0.10 14 2/2
YFV_pp3377-3391 NS5 (871-885)     IHRIRTLIGQEKYTD DRB1*04:04 1.80 27 2/2
Table SV. A complete list of the 50 CD4+ T cell epitopes identified by the HFRI approach.
The CD4+ T cell epitope discovery process detailed for donor YF1067 was extended to 50 randomely selected, primary YFV 
vaccinated donors. 50 different CD4+ T cell responses restricted by 14 HLA-II allotypes (13 HLA-DR-restricted and one HLA-
DP-restricted) were discovered. The peptide-HLA-I affinities were predicted by NetMHCIIpan (given in %Rank) and the 
binding affinity was measured (given in nM) (the lower the prediction or measurement, the better the affinity). Productively 
interacting peptide-HLA-II combinations were used to design and generate peptide-HLA class II tetramers. The resulting 
tetramers were used to stain and analyze expanded CD4+ T cells by flow cytometry gating on CD3+ CD4+ T cells. The 
prevalence of these responses is given as "the number of responding donors/the number of donors tested".
In the event that two overlapping peptides were identified, the overlapping sequence has been colored red. For solubilization 
purpose, lysines have in some cases been added to the N- or C-terminal of the peptide (indicated here by underlining these added 
lysines.
